<SEC-DOCUMENT>0001213900-26-086768.txt : 20260807
<SEC-HEADER>0001213900-26-086768.hdr.sgml : 20260807
<ACCEPTANCE-DATETIME>20260807170017
ACCESSION NUMBER:		0001213900-26-086768
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20260805
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260807
DATE AS OF CHANGE:		20260807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			iSpecimen Inc.
		CENTRAL INDEX KEY:			0001558569
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				270480143
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40501
		FILM NUMBER:		261255211

	BUSINESS ADDRESS:	
		STREET 1:		8 CABOT ROAD
		STREET 2:		SUITE 1800
		CITY:			WOBURN
		STATE:			MA
		ZIP:			08101
		BUSINESS PHONE:		781-301-6700

	MAIL ADDRESS:	
		STREET 1:		8 CABOT ROAD
		STREET 2:		SUITE 1800
		CITY:			WOBURN
		STATE:			MA
		ZIP:			08101
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0301006-8k_ispecimen.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:us-roles="http://fasb.org/us-roles/2026" xmlns:country="http://xbrl.sec.gov/country/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:ISPC="http://ispecimen.com/20260805">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02F_US%2DGAAP%2D2026 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_ISPC_ispecimen.com_20260805 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20260805_20260805 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0001558569 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2026-08-05" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-08-05" id="Fact000004" name="dei:EntityCentralIndexKey">0001558569</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ispc-20260805.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2026-08-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001558569</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-08-05</xbrli:startDate>
        <xbrli:endDate>2026-08-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM&#160;<span id="xdx_907_edei--DocumentType_c20260805__20260805_zX3cgx94Wqo8"><ix:nonNumeric contextRef="AsOf2026-08-05" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PURSUANT
TO SECTION 13 OR 15(d)<br/>
OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported): <span id="xdx_903_edei--DocumentPeriodEndDate_c20260805__20260805_z9biF2wOaK11"><ix:nonNumeric contextRef="AsOf2026-08-05" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">August 5, 2026</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityRegistrantName_c20260805__20260805_zuMpUghsqsH5"><ix:nonNumeric contextRef="AsOf2026-08-05" id="Fact000011" name="dei:EntityRegistrantName">iSpecimen
Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20260805__20260805_zg7DhdhTTscc"><ix:nonNumeric contextRef="AsOf2026-08-05" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityFileNumber_c20260805__20260805_zbT0k7FcSfNh"><ix:nonNumeric contextRef="AsOf2026-08-05" id="Fact000013" name="dei:EntityFileNumber">001-40501</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityTaxIdentificationNumber_c20260805__20260805_zPtYsrFrlk37"><ix:nonNumeric contextRef="AsOf2026-08-05" id="Fact000014" name="dei:EntityTaxIdentificationNumber">27-0480143</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
    or other jurisdiction<br/>
    of Incorporation)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission
    File Number)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS
    Employer<br/>
    Identification No.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_90F_edei--EntityAddressAddressLine1_c20260805__20260805_z3rxk3kzPIPh"><ix:nonNumeric contextRef="AsOf2026-08-05" id="Fact000015" name="dei:EntityAddressAddressLine1">8 Cabot
    Road</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressAddressLine2_c20260805__20260805_zBVGzGx0AAw1"><ix:nonNumeric contextRef="AsOf2026-08-05" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 1800</ix:nonNumeric></span></span><br/>
    <span id="xdx_901_edei--EntityAddressCityOrTown_c20260805__20260805_zJPJEF4r7JG7"><ix:nonNumeric contextRef="AsOf2026-08-05" id="Fact000017" name="dei:EntityAddressCityOrTown">Woburn</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20260805__20260805_zbziMzIHne2c"><ix:nonNumeric contextRef="AsOf2026-08-05" id="Fact000018" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span> <span id="xdx_906_edei--EntityAddressPostalZipCode_c20260805__20260805_zqd6olceprQi"><ix:nonNumeric contextRef="AsOf2026-08-05" id="Fact000019" name="dei:EntityAddressPostalZipCode">01801</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address of principal
    executive offices, including zip code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code: <span>(<span id="xdx_907_edei--CityAreaCode_c20260805__20260805_z1A4sc65PnIi"><ix:nonNumeric contextRef="AsOf2026-08-05" id="Fact000020" name="dei:CityAreaCode">781</ix:nonNumeric></span>)</span> <span id="xdx_906_edei--LocalPhoneNumber_c20260805__20260805_zIztbuMVuUF8"><ix:nonNumeric contextRef="AsOf2026-08-05" id="Fact000021" name="dei:LocalPhoneNumber">301-6700</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>Not
Applicable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Former
name or former address, if changed since last report)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form&#160;8-K&#160;filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_90A_edei--WrittenCommunications_c20260805__20260805_zXCzpXEGnjkl"><ix:nonNumeric contextRef="AsOf2026-08-05" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications
    pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_901_edei--SolicitingMaterial_c20260805__20260805_zEDo4X75juE2"><ix:nonNumeric contextRef="AsOf2026-08-05" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant
    to Rule&#160;14a-12&#160;under the Exchange Act (17 CFR&#160;240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_905_edei--PreCommencementTenderOffer_c20260805__20260805_zaLH0mXahNGl"><ix:nonNumeric contextRef="AsOf2026-08-05" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement&#160;communications
    pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR&#160;240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_904_edei--PreCommencementIssuerTenderOffer_c20260805__20260805_z5UkZbGVImF7"><ix:nonNumeric contextRef="AsOf2026-08-05" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement&#160;communications
    pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR&#160;240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section&#160;12(b)&#160;of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--Security12bTitle_c20260805__20260805_zTlTrGwTRPy2"><ix:nonNumeric contextRef="AsOf2026-08-05" id="Fact000026" name="dei:Security12bTitle">Common
    Stock, par value $0.0001 per share</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--TradingSymbol_c20260805__20260805_z0E60XAdXik4"><ix:nonNumeric contextRef="AsOf2026-08-05" id="Fact000027" name="dei:TradingSymbol">ISPC</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--SecurityExchangeName_c20260805__20260805_zXPksOcX4Qzf"><ix:nonNumeric contextRef="AsOf2026-08-05" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market LLC</ix:nonNumeric></span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934&#160;(&#167;240.12b-2&#160;of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_902_edei--EntityEmergingGrowthCompany_c20260805__20260805_zyRGgtQrdNig"><ix:nonNumeric contextRef="AsOf2026-08-05" format="ixt:booleantrue" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span id="xdx_905_edei--EntityExTransitionPeriod_c20260805__20260805_z7iYp6qxof15"><ix:nonNumeric contextRef="AsOf2026-08-05" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01 Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>On
August 5, 2026, iSpecimen Inc. (the &#8220;Company&#8221;) entered into a placement agency agreement (the &#8220;Placement Agency Agreement&#8221;)
with E.F. Hutton &amp; Co. (the &#8220;Placement Agent&#8221;), and a securities purchase agreement (the &#8220;Purchase Agreement&#8221;)
with investors&#160;in connection with which the Company agreed to issue and sell, in a&#160;&#8220;reasonable&#160;best efforts&#8221; public
offering&#160;(the &#8220;Offering&#8221;) (i) 996,231 shares (the &#8220;Shares&#8221;)&#160;of the Company&#8217;s common stock, par
value $0.0001 per share (the &#8220;Common Stock&#8221;), and (ii) pre-funded warrants to purchase up to 2,849,923 shares of Common Stock
(the &#8220;Pre-Funded Warrants&#8221;) for an aggregate purchase price of $5,000,000 (or $5,000,285 assuming the full exercise of the Pre-Funded Warrants), before deducting placement agent fees and
other offering expenses.&#160;As part of its compensation for acting as Placement Agent for the Offering, the Company paid the Placement
Agent a cash fee of 4.0% of the aggregate gross proceeds plus reimbursement of certain expenses and legal fees and a 1% non-accountable
expense allowance.&#160;The Company intends to use the proceeds of the offering for repayment of outstanding liabilities, potential acquisitions
of assets or investments in businesses, products and technologies, and for marketing and advertising services. The remainder of the proceeds
will be used for working capital purposes.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span>The
Placement Agency Agreement and the Purchase Agreement each contain customary representations, warranties and agreements by the Company,
customary conditions to closing, indemnification obligations of the Company, the Placement Agent, or the purchasers in the Offering,
as the case may be, and other obligations of the parties and termination provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering closed on August 7, 2026. The securities sold in the Offering were offered and sold pursuant to a registration statement on&#160;Form
S-1 (File No. 333-297001), which was filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) on June 24, 2026,
and subsequently declared effective by the Commission on July 30, 2026.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing description of the material terms of the Placement Agency Agreement, the Purchase Agreement and the Pre-Funded Warrant is not
complete and is qualified in its entirety by reference to the full text of the form of Placement Agency Agreement, Purchase Agreement
and Pre-Funded Warrant, copies of which are filed as Exhibits 4.1, 10.1 and 10.2, respectively, to this Current Report on Form 8-K and
are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
7.01&#160;Regulation FD&#160;Disclosure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 6, 2026, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is furnished as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. On August 7, 2026, the Company
issued a press release announcing the closing of the Offering. A copy of the press release is furnished as Exhibit 99.2 to this Current
Report on Form 8-K and is incorporated into this Item 7.01 by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01 Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 8%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit<br/>
    No.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left; width: 2%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 90%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea030100601ex4-1.htm">Form of&#160;Pre-Funded Warrant</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea030100601ex10-1.htm">Form of&#160;Placement Agency Agreement</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea030100601ex10-2.htm">Form of&#160;Securities Purchase Agreement</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea030100601ex99-1.htm">Press Release dated August 6, 2026, announcing the pricing of the Offering</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea030100601ex99-2.htm">Press Release dated August 7, 2026, announcing the closing of the Offering</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the
    Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
August 7, 2026</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iSPECIMEN INC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Katharyn Field</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Katharyn
    Field</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKwjAMRb9g/xD6LLObOGSPjiniFBkivhaXSXFrRlp1fpJ/ad0QQyAk955cISZiTSvdIMN5WRZwxLZrlEMosUZGc0HvyDbbFPws8aqtY2XcsP7AjDyDnknC+cXfB+dDW6xSkIupTKZxAnKWzhdw2Ingq2dkal2hcVo1oEwFB6aONTrFr/HDUfVkqH0NSSdkq8mkEIVylN8QyyiGPT3Uk/hmoSgyEUyGCsSa6d55V947NF8S8gZbH2dH+t/BB9VpSmw= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ea030100601ex4-1.htm
<DESCRIPTION>FORM OF PRE-FUNDED WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRE-FUNDED COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>iSpecimen Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrant Shares: _______&#9;Initial Exercise Date: ______, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT
(the &ldquo;Warrant&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;Holder&rdquo;) is entitled, upon
the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth
above (the &ldquo;Initial Exercise Date&rdquo;) and until this Warrant is exercised in full (the &ldquo;Termination Date&rdquo;) but not
thereafter, to subscribe for and purchase from iSpecimen Inc., a Delaware corporation (the &ldquo;Company&rdquo;), up to ______ shares
(as subject to adjustment hereunder, the &ldquo;Warrant Shares&rdquo;) of the Company&rsquo;s Common Stock. The purchase price of one
share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 1. Definitions.</B> In addition to
the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Affiliate&rdquo;</B> means any Person
that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person,
as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Bid Price&rdquo;</B> means, for any
date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading
Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the
Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m.
(New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date
(or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB
or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases,
the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a
majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be
paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Business Day&rdquo;</B> means any day
other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain
closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed
due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo; or any other similar orders or
restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic
funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers
on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Commission&rdquo;</B> means the United
States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Common Stock&rdquo;</B> means the common
stock of the Company, par value $0.0001 per share, and any other class of securities into which such securities may hereafter be reclassified
or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Common Stock Equivalents&rdquo;</B>
means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including,
without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable
or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Exchange Act&rdquo;</B> means the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Person&rdquo;</B> means an individual
or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock
company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Purchase Agreement&rdquo;</B> means
the securities purchase agreement, dated as of _____, 2026, by and between the Company and each of the purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Registration Statement&rdquo;</B> means
the Company&rsquo;s registration statement on Form S-1 (File No. 333-297001).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Securities Act&rdquo;</B> means the
Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Subsidiary&rdquo;</B> means any subsidiary
of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the
date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Trading Day&rdquo;</B> means a day on
which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Trading Market&rdquo;</B> means any
of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American,
the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors
to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Transfer Agent&rdquo;</B> means Broadridge
Corporate Issuer Solutions LLC, the current transfer agent of the Company, with a mailing address of 51 Mercedes Way, Edgewood, NY 11717,
and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;VWAP&rdquo;</B> means, for any date,
the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading
Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market
on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time)
to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock
for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for
trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency
succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other
cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders
of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall
be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Warrants&rdquo;</B> means this Warrant
and other pre-funded Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 2. Exercise.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a) <B><I>Exercise of Warrant.</I></B> Exercise
of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise
Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment)
of the Notice of Exercise in the form annexed hereto (the &ldquo;Notice of Exercise&rdquo;). Within the earlier of (i) one (1) Trading
Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the
date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable
Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified
in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall
any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein
to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all
of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant
to the Company for cancellation as soon as reasonably practicable following the date on which the final Notice of Exercise is delivered
to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable
number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and
the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of
such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this
paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder
at any given time may be less than the amount stated on the face hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b) <B><I>Exercise Price.</I></B> The aggregate
exercise price of this Warrant, except for a nominal exercise price of $0.0001 per Warrant Share, was pre-funded to the Company on or
prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise price of $0.0001 per
Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The Holder shall not be
entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for any reason
whatsoever. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be $0.0001, subject to adjustment hereunder
(the &ldquo;Exercise Price&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">c) <B><I>Cashless Exercise.</I></B> This Warrant
may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled
to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(A) = as applicable: (i) the VWAP on
the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and
delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a)
hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated
under the federal securities laws) on such Trading Day, (ii) the Bid Price of the Common Stock on the principal Trading Market as reported
by Bloomberg L.P. (&ldquo;Bloomberg&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such
Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter
(including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof,
or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice
of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such
Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(B) = the Exercise Price of this Warrant,
as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(X) = the number of Warrant Shares that
would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash
exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Warrant Shares are issued in such a cashless
exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take
on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary to this Section
2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">d) <B><I>Mechanics of Exercise.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">i. Delivery of Warrant Shares Upon Exercise.
The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the
account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit or Withdrawal
at Custodian system (&ldquo;DWAC&rdquo;) if the Company is then a participant in such system and either (A) there is an effective registration
statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being
exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register
in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise
to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after delivery
of the aggregate Exercise Price to the Company (if applicable), and (ii) the number of Trading Days comprising the Standard Settlement
Period, in each case (i) or (ii), after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;Warrant Share Delivery
Date&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder
of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant
Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant
Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by
the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000
of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $5
per Trading Day (increasing to $10 per Trading Day on the fifth (5th) Trading Day after the Warrant Share Delivery Date) for each Trading
Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees
to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As
used herein, &ldquo;Standard Settlement Period&rdquo; means the standard settlement period, expressed in a number of Trading Days, on
the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.
Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 4:00 p.m. (New York City time) one Trading
Day prior to the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the
Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date
and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate
Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">ii. Delivery of New Warrants Upon Exercise.
If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate,
at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the
unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">iii. Rescission Rights. If the Company
fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery
Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">iv. Compensation for Buy-In on Failure
to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause
the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to
an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in
an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in
satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;Buy-In&rdquo;),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including
brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number
of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price
at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the
portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall
be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely
complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase
price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving
rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay
the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the
Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue
any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or
injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as
required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">v. No Fractional Shares or Scrip. No
fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share
which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment
in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">vi. Charges, Taxes and Expenses. Issuance
of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the
issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued
in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event that Warrant
Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by
the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a
sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day
processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing
similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">vii. Closing of Books. The Company will
not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">e) <B><I>Holder&rsquo;s Exercise Limitations.</I></B>
The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant,
pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable
Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting as a group together with the
Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;Attribution Parties&rdquo;)), would beneficially own in excess of
the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially
owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise
of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would
be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company
(including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the
limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the
preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing
to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission
of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable,
in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy
of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining
the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in
(A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public
announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares
of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally
and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the
Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.
The &ldquo;Beneficial Ownership Limitation&rdquo; shall be [4.99%][9.99%] of the number of shares of Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company,
may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation
in no event exceeds 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares
of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any
increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company.
The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of
this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial
Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation.
The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 3. Certain Adjustments.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a) <B><I>Stock Dividends and Splits.</I></B> If
the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions
on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance
of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding
shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of
Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock
of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares
of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the
number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant
shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant
to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive
such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b) <B><I>Subsequent Rights Offerings.</I></B>
In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents
or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock
(the &ldquo;Purchase Rights&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the
aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights,
or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant,
issue or sale of such Purchase Rights (provided, however, that to the extent that the Holder&rsquo;s right to participate in any such
Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such
extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">c) <B><I>Pro Rata Distributions.</I></B> During
such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights
to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation,
any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement,
scheme of arrangement or other similar transaction) (a &ldquo;Distribution&rdquo;), at any time after the issuance of this Warrant, then,
in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated
therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard
to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of
Common Stock are to be determined for the participation in such Distribution (provided, however, that to the extent that the Holder&rsquo;s
right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock
as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the
Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">d) <B><I>Fundamental Transaction.</I></B> If,
at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any
merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary), directly or indirectly, effects
any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of the assets of the Company
in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by
the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their
shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding Common Stock
or greater than 50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more
related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange
pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company,
directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or
group of Persons whereby such other Person or group acquires greater than 50% of the outstanding shares of Common Stock or greater than
50% of the voting power of the common equity of the Company (each a &ldquo;Fundamental Transaction&rdquo;), then, upon any subsequent
exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise
immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in
Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the
Company, if it is the surviving corporation, and any additional consideration (the &ldquo;Alternate Consideration&rdquo;) receivable as
a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately
prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the
Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any
different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property
to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives
upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the &ldquo;Successor Entity&rdquo;) to assume in writing all of the obligations
of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance
reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and
shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by
a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares
of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon
exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and
with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative
value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number
of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder.
Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo; under this
Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant
referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly
and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power
of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto
under this Warrant with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had
been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section
3(d) regardless of (i) whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or
(ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">e) <B><I>Calculations.</I></B> All calculations
under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section
3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares
of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">f) <B><I>Notice to Holder.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">i. Adjustment to Exercise Price. Whenever
the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email
a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting
forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">ii. Notice to Allow Exercise by Holder.
If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare
a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders
of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the
approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation
or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets,
or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall
authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company
shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company,
at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which
a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken,
the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants
are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected
to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to
exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation,
merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof
shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided
in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to
exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice
except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">g) <B><I>Voluntary Adjustment By Company.</I></B>
Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of this Warrant reduce the then
current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 4. Transfer of Warrant.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a) <B><I>Transferability.</I></B> This Warrant
and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender
of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially
in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable
upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant
or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument
of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant
shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant
to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this
Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant
Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b) <B><I>New Warrants.</I></B> This Warrant may
be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice
specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject
to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and
deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All
Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with this Warrant except
as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">c) <B><I>Warrant Register.</I></B> The Company
shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;Warrant Register&rdquo;), in the
name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute
owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice
to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 5. Miscellaneous.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a) <B><I>No Rights as Stockholder Until Exercise;
No Settlement in Cash.</I></B> This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder
of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting
any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to Section 2(c) or to receive cash payments
pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this
Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b) <B><I>Loss, Theft, Destruction or Mutilation
of Warrant.</I></B> The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft,
destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction,
of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond),
and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant
or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">c) <B><I>Saturdays, Sundays, Holidays, etc..</I></B>
If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading
Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">d) <B><I>Authorized Shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company covenants that, during the period
the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for
the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its
issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant
Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary
to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements
of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon
the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant
and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free
from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer
occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except and to the extent as waived or consented
to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through
any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in
the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder
as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the
par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value,
(ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable
Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations
under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before taking any action which would result in
an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain
all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having
jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">e) <B><I>Governing Law.</I></B> All questions
concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced
in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party
agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant
(whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees
or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication
of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably
waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of
any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably
waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof
via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices
to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party
shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding
shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">f) <B><I>Restrictions.</I></B> The Holder acknowledges
that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise,
will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">g) <B><I>Nonwaiver and Expenses.</I></B> No course
of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise
prejudice the Holder&rsquo;s rights, powers or remedies, notwithstanding the fact that the right to exercise this Warrant terminates on
the Termination Date. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with
any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as
shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of
appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights,
powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">h) <B><I>Notices.</I></B> Any and all notices
or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Exercise, shall
be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company,
at 8 Cabot Road, Suite 1800, Woburn, MA 01801, Attention: Katharyn Field, Chief Executive Officer, email address: [&#9679;], or such other
email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications
or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally
recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of
the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the
time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior to
5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication
is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New
York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">i) <B><I>Limitation of Liability.</I></B> No provision
hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration
herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common
Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">j) <B><I>Remedies.</I></B> The Holder, in addition
to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its
rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason
of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific
performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">k) <B><I>Successors and Assigns.</I></B> Subject
to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding
upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant
are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of
Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">l) <B><I>Amendment.</I></B> Other than Section
2(e) above and this Section 5(l), which may not be amended, modified or waived, this Warrant may be modified or amended or the provisions
hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">m) <B><I>Severability.</I></B> Wherever possible,
each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision
of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition
or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">n) <B><I>Headings.</I></B> The headings used in
this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>********************</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, the Company has caused this
Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2" STYLE="text-align: left"><B>iSpecimen Inc.</B></TD><TD STYLE="text-align: justify"><B>&nbsp;</B></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 5%">By:</TD>
<TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 35%">&nbsp;</TD><TD STYLE="text-align: justify; width: 60%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">Name:</TD>
<TD STYLE="text-align: left">Katharyn Field</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">Title:</TD>
<TD STYLE="text-align: left"> Chief Executive Officer</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To: iSpecimen Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The undersigned hereby elects to purchase
________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith
payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Payment shall take the form of (check applicable
box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">in lawful money of the United States; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">the cancellation of such number of Warrant Shares as is necessary,
in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares
purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Please issue said Warrant Shares in the name
of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[SIGNATURE OF HOLDER]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: _______________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature of Authorized Signatory of Investing
Entity: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(To assign the foregoing Warrant, execute this
form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name: _______________________________ (Please
Print)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address: _______________________________ (Please
Print)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phone Number: _______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email Address: _______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: _______________ __, ______</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holder&rsquo;s Signature: ________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holder&rsquo;s Address: _________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ea030100601ex10-1.htm
<DESCRIPTION>FORM OF PLACEMENT AGENCY AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLACEMENT AGENCY AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[*], 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">E.F. Hutton &amp; Co.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">745 Fifth Avenue, 34th Floor &amp; PH</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10151</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This letter (the &ldquo;Agreement&rdquo;) constitutes
the agreement between E.F. Hutton &amp; Co. (&ldquo;EF Hutton&rdquo; or the &ldquo;Placement Agent&rdquo;) and iSpecimen Inc., a Delaware
corporation (the &ldquo;Company&rdquo;), pursuant to which the Placement Agent shall serve as the placement agent for the Company, on
a &ldquo;reasonable best efforts&rdquo; basis, in connection with the proposed placement (the &ldquo;Placement&rdquo;) of shares (the
&ldquo;Shares&rdquo;) of the Company&rsquo;s common stock, $0.0001 par value per share (the &ldquo;Common Stock&rdquo;), and/or, in lieu
of Shares, pre-funded warrants to purchase shares of Common Stock (the &ldquo;Pre-Funded Warrants&rdquo;) to certain investors whose purchase
of Shares would otherwise result in beneficial ownership in excess of the applicable beneficial ownership limitation (the shares of Common
Stock issuable upon exercise of the Pre-Funded Warrants, the &ldquo;Warrant Shares&rdquo;; and the Shares, the Pre-Funded Warrants and
the Warrant Shares, collectively, the &ldquo;Securities&rdquo;), to be sold by the Company directly to various investors (each, an &ldquo;Investor&rdquo;
and, collectively, the &ldquo;Investors&rdquo;). The documents executed and delivered by the Company and the Investors in connection with
the Offering (as defined below), including, without limitation, a securities purchase agreement (the &ldquo;Purchase Agreement&rdquo;),
shall be collectively referred to herein as the &ldquo;Transaction Documents.&rdquo; The purchase price to the Investors for the Securities
will be determined based on negotiation between the Company, the Placement Agent and the Investors. The Placement Agent may retain other
brokers or dealers to act as sub-agents or selected-dealers on its behalf in connection with the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company hereby confirms its agreement with
the Placement Agent as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 1. Agreement to Act as Placement Agent.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) On the basis of the representations, warranties
and agreements of the Company herein contained, and subject to all the terms and conditions of this Agreement, the Placement Agent shall
be the exclusive placement agent in connection with the offering and sale by the Company of the Securities pursuant to the Company&rsquo;s
registration statement on Form S-1 (File No. 333-297001) (and including any registration statement prepared and filed by the Company in
accordance with Rule 462(b) under the Securities Act) (the &ldquo;Registration Statement&rdquo;), with the terms of such offering (the
&ldquo;Offering&rdquo;) to be subject to market conditions and negotiations between the Company, the Placement Agent and the prospective
Investors. The Placement Agent will act on a reasonable best efforts basis and the Company agrees and acknowledges that there is no guarantee
of the successful placement of the Securities, or any portion thereof, in the prospective Offering. Under no circumstances will the Placement
Agent or any of its &ldquo;Affiliates&rdquo; (as defined below) be obligated to underwrite or purchase any of the Securities for its own
account or otherwise provide any financing. The Placement Agent shall act solely as the Company&rsquo;s agent and not as principal. The
Placement Agent shall have no authority to bind the Company or any Investor or impose any obligation on the Company with respect to any
prospective offer to purchase Securities, issuance of Securities or completion of the Placement, and the Company shall have the sole right
to accept offers to purchase Securities and may reject any such offer, in whole or in part. Subject to the terms and conditions hereof,
payment of the purchase price for, and delivery of, the Securities shall be made at one or more closings (each a &ldquo;Closing&rdquo;
and the date on which each Closing occurs, a &ldquo;Closing Date&rdquo;). The Closing of the issuance of the Securities shall occur via
&ldquo;Delivery Versus Payment,&rdquo; i.e., on the Closing Date, the Company shall issue the Securities directly to the account (or accounts)
designated by the Placement Agent and, upon receipt of such Securities, the Placement Agent shall electronically deliver such Securities
to the applicable Investor and payment shall be made by the Placement Agent (or its clearing firm) by wire transfer to the Company. As
compensation for services rendered, on each Closing Date, the Company shall pay to the Placement Agent the consideration set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i) a cash fee equal to 4.0% of the
aggregate gross proceeds received by the Company from the sale of the Securities at such Closing (the &ldquo;Cash Fee&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ii) a non-accountable expense allowance
equal to 1.0% of the aggregate gross proceeds received by the Company from the sale of the Securities at such Closing (the &ldquo;Non-Accountable
Expense Fee&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing fees are due and payable to the
Placement Agent immediately upon each Closing of the Offering and shall be disbursed to the Placement Agent simultaneously with the delivery
of the proceeds of the Offering to the Company via wire transfer of immediately available funds pursuant to the flow of funds for such
Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) The term of the Placement Agent&rsquo;s exclusive
engagement (the &ldquo;Term&rdquo;) will be as set forth in the Engagement Letter (as defined below). Notwithstanding anything to the
contrary contained herein, the provisions concerning the payment of fees, the reimbursement of expenses, the Tail (as defined below),
, indemnification and contribution, confidentiality, and the Company&rsquo;s obligations contained in the indemnification provisions will
survive any expiration or termination of this Agreement, and the Company&rsquo;s obligation to pay fees actually earned and payable and
to reimburse expenses actually incurred and reimbursable pursuant to Section 1 and Section 6 hereof, in each case which are permitted
to be reimbursed under Financial Industry Regulatory Authority (&ldquo;FINRA&rdquo;) Rule 5110(g)(5)(A), will survive any expiration or
termination of this Agreement. Notwithstanding the foregoing, the Company shall have the right to terminate this Agreement for cause in
compliance with FINRA Rule 5110(g)(5)(B)(i), and the exercise of such right of termination for cause shall eliminate the Company&rsquo;s
obligations with respect to the provisions relating to the Tail set forth in Sections 1(c) and 1(d), respectively. Nothing in this Agreement
shall be construed to limit the ability of the Placement Agent or its Affiliates to pursue, investigate, analyze, invest in, or engage
in investment banking, financial advisory or any other business relationship with Persons (as defined below) other than the Company. As
used herein (i) &ldquo;Persons&rdquo; means an individual or corporation, partnership, trust, incorporated or unincorporated association,
joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any
kind and (ii) &ldquo;Affiliate&rdquo; means any Person that, directly or indirectly through one or more intermediaries, controls or is
controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act
of 1933, as amended (the &ldquo;Securities Act&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) <B><I>Tail. </I></B>Upon a Closing of the
Offering, or if this Agreement expires or is terminated (other than a termination by the Company for cause in compliance with FINRA Rule
5110(g)(5)(B)(i)), the Placement Agent shall be entitled to the compensation set forth in Section 1(a) hereof, calculated in the manner
set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of any kind (each,
a &ldquo;Tail Financing&rdquo;) to the extent that such financing or capital is provided to the Company by investors whom the Placement
Agent had introduced, directly or indirectly, to the Company during the Term, if such Tail Financing is consummated at any time within
the twelve (12) month period following the expiration or termination of this Agreement (the &ldquo;Tail Period&rdquo;). The Company shall
pay such compensation to the Placement Agent upon the closing of any such Tail Financing or the receipt by the Company of any such proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) <B><I>Reserved.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 2. Representations, Warranties and
Covenants of the Company. </B>The Company hereby represents, warrants and covenants to the Placement Agent as of the date hereof, and
as of each Closing Date, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) <B><I>Securities Law Filings. </I></B>The
Company has filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) the Registration Statement under the Securities
Act, which was initially filed on June 24, 2026, as amended, and declared effective on [*], 2026 for the registration of the Securities
under the Securities Act. Following the determination of pricing among the Company and the prospective Investors introduced to the Company
by the Placement Agent, the Company will file with the Commission pursuant to Rules 430A and 424(b) under the Securities Act, and the
rules and regulations (the &ldquo;Rules and Regulations&rdquo;) of the Commission promulgated thereunder, a final prospectus relating
to the placement of the Securities, their respective pricings and the plan of distribution thereof, and will advise the Placement Agent
of all further information (financial and other) with respect to the Company required to be set forth therein. Such registration statement,
at any given time, including the exhibits thereto filed at such time, as amended at such time, is hereinafter called the &ldquo;Registration
Statement&rdquo;; such prospectus in the form in which it appears in the Registration Statement at the time of effectiveness is hereinafter
called the &ldquo;Preliminary Prospectus&rdquo;; and the final prospectus, in the form in which it will be filed with the Commission pursuant
to Rules 430A and/or 424(b) (including the Preliminary Prospectus as it may be amended or supplemented) is hereinafter called the &ldquo;Final
Prospectus.&rdquo; Any reference in this Agreement to the Registration Statement, the Preliminary Prospectus or the Final Prospectus shall
be deemed to refer to and include the documents incorporated by reference therein (the &ldquo;Incorporated Documents&rdquo;), if any,
which were or are filed under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), at any given time. As
used herein, &ldquo;Time of Sale Disclosure Package&rdquo; means the Preliminary Prospectus, any securities purchase agreement between
the Company and the Investors, the final terms of the Offering provided to the Investors (orally or in writing) and any issuer free writing
prospectus as defined in Rule 433 of the Securities Act, if any, that the parties hereto shall hereafter expressly agree in writing to
treat as part of the Time of Sale Disclosure Package. The Company has not received any notice that the Commission has issued or intends
to issue a stop order suspending the effectiveness of the Registration Statement or the use of the Preliminary Prospectus or any prospectus
supplement or intends to commence a proceeding for any such purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) <B><I>Assurances. </I></B>The Registration
Statement (and any further documents to be filed with the Commission) contains all exhibits and schedules as required by the Securities
Act. Each of the Registration Statement and any post-effective amendment thereto, at the time it became effective, complied in all material
respects with the Securities Act and the applicable Rules and Regulations and did not contain any untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. The Preliminary
Prospectus and the Final Prospectus, each as of its respective date, comply or will comply in all material respects with the Securities
Act and the applicable Rules and Regulations, and did not and will not contain as of the date thereof any untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they
were made, not misleading. The Incorporated Documents, when they were filed with the Commission, conformed in all material respects to
the requirements of the Exchange Act and the applicable Rules and Regulations promulgated thereunder, and none of such documents, when
they were filed with the Commission, contained any untrue statement of a material fact or omitted to state a material fact necessary to
make the statements therein, in light of the circumstances under which they were made, not misleading. Except for this Agreement and the
Transaction Documents, there are no contracts or other documents required to be described in the Preliminary Prospectus or Final Prospectus,
or to be filed as exhibits or schedules to the Registration Statement, which have not been described or filed as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) <B><I>Offering Materials. </I></B>Neither
the Company nor any of its directors and officers has distributed and none of them will distribute, prior to each Closing Date, any offering
material in connection with the offering and sale of the Securities other than the Time of Sale Disclosure Package.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) <B><I>Authorization; Enforcement. </I></B>The
Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement
and the Time of Sale Disclosure Package and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery
of this Agreement by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized
by all necessary action on the part of the Company and no further action is required by the Company, the Company&rsquo;s Board of Directors
(the &ldquo;Board of Directors&rdquo;) or the Company&rsquo;s shareholders in connection therewith. This Agreement has been duly executed
by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company
enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally,
(ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)
insofar as indemnification and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(e) <B><I>No Conflicts. </I></B>The execution,
delivery and performance by the Company of this Agreement and the transactions contemplated pursuant to the Time of Sale Disclosure Package,
the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will
not (i) conflict with or violate any provision of the Company&rsquo;s or any subsidiary&rsquo;s certificate or articles of incorporation,
bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse
of time or both would become a default) under, result in the creation of any lien upon any of the properties or assets of the Company
or any subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse
of time or both) of, any agreement, credit facility, debt or other instrument or other understanding to which the Company or any subsidiary
is a party or by which any property or asset of the Company or any subsidiary is bound or affected, or (iii) conflict with or result in
a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority
to which the Company or a subsidiary is subject (including federal and state securities laws and regulations), or by which any property
or asset of the Company or a subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not
have or reasonably be expected to result in a Material Adverse Effect, as defined in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(f) <B><I>Certificates. </I></B>Any certificate
signed by an officer of the Company and delivered to the Placement Agent or to counsel for the Placement Agent shall be deemed to be a
representation and warranty by the Company to the Placement Agent as to the matters set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(g) <B><I>Reliance. </I></B>The Company acknowledges
that the Placement Agent will rely upon the accuracy and truthfulness of the foregoing representations and warranties and hereby consents
to such reliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(h) <B><I>Forward-Looking Statements. </I></B>No
forward-looking statements (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) contained in
the Time of Sale Disclosure Package has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) <B><I>Statistical or Market-Related Data.
</I></B>Any statistical, industry-related and market-related data included or incorporated by reference in the Time of Sale Disclosure
Package are based on or derived from sources that the Company reasonably and in good faith believes to be reliable and accurate, and such
data agree with the sources from which they are derived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(j) <B><I>Certain Fees; FINRA Affiliations. </I></B>Except
as set forth in the Registration Statement and the Prospectus, no brokerage or finder&rsquo;s fees or commissions are or will be payable
by the Company, any subsidiary or Affiliate of the Company to any broker, financial advisor or consultant, finder, placement agent, investment
banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. There are no other arrangements,
agreements or understandings of the Company or, to the Company&rsquo;s knowledge, any of its shareholders that may affect the Placement
Agent&rsquo;s compensation, as determined by FINRA. To the Company&rsquo;s knowledge, no officer, director or any beneficial owner of
10% or more of the Company&rsquo;s Common Stock or Common Stock Equivalents (as defined in the Purchase Agreement) has any direct or indirect
affiliation or association with any FINRA member participating in the Offering (a &ldquo;Participating Member&rdquo;). No proceeds from
the sale of the Securities (excluding Placement Agent compensation as disclosed in the Registration Statement and the Prospectus) will
be paid to any Participating Member, any persons associated with a Participating Member or an affiliate of a Participating Member. The
Company will advise the Placement Agent and its legal counsel, Zarif Law Group P.C. (&ldquo;Placement Agent Counsel&rdquo;), if it learns
that any officer, director or owner of 10% or more of the Company&rsquo;s outstanding Common Stock or Common Stock Equivalents is or becomes
an affiliate or associated person of a Participating Member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(k) <B><I>Board of Directors. </I></B>The Board
of Directors is comprised of the persons set forth under the applicable heading of the Company&rsquo;s most recent Annual Report on Form
10-K, as updated by the Company&rsquo;s subsequent filings with the Commission. The qualifications of the persons serving as board members
and the overall composition of the Board of Directors comply with the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder
applicable to the Company and the rules of The Nasdaq Stock Market LLC (the &ldquo;Trading Market&rdquo;). At least a majority of the
persons serving on the Board of Directors qualify as &ldquo;independent&rdquo; as defined under the rules of the Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(l) <B><I>D&amp;O Questionnaires. </I></B>To the
Company&rsquo;s knowledge, all information contained in the questionnaires most recently completed by each of the Company&rsquo;s directors
and officers is true and correct in all respects and the Company has not become aware of any information which would cause the information
disclosed in such questionnaires to become inaccurate and incorrect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(m) <B><I>Representations, Warranties and Covenants
Incorporated by Reference. </I></B>Each of the representations, warranties and covenants (together with any related disclosure schedules
thereto) made to the Investors in the Purchase Agreement is hereby incorporated herein by reference (as though fully restated herein)
and is hereby made to, and in favor of, the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 3. Delivery and Payment. </B>Each Closing
shall occur at the offices of the Placement Agent Counsel at 808 Springwood Avenue, Suite 110, Asbury Park, NJ 07712 (or at such other
place as shall be agreed upon by the Placement Agent and the Company, including via remote transmission of Closing documentation and the
Transaction Documents). Subject to the terms and conditions hereof, at each Closing payment of the purchase price for the Securities sold
on such Closing Date shall be made by Federal Funds wire transfer, against delivery of such Securities, and such Securities shall be registered
in such name or names and shall be in such denominations as the Placement Agent may request at least one business day before the time
of purchase. Deliveries of the documents with respect to the purchase of the Securities, if any, shall be made at the offices of Placement
Agent Counsel. All actions taken at a Closing shall be deemed to have occurred simultaneously.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 4. Covenants and Agreements of the
Company. </B>The Company further covenants and agrees with the Placement Agent as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) <B><I>Registration Statement Matters. </I></B>The
Company will advise the Placement Agent promptly after it receives notice thereof of the time when any amendment to the Registration Statement
has been filed or becomes effective or any supplement to the Final Prospectus has been filed and will furnish the Placement Agent with
copies thereof. The Company will file promptly all reports and any definitive proxy or information statements required to be filed by
the Company with the Commission pursuant to Section 13(a), 14 or 15(d) of the Exchange Act subsequent to the date of any Prospectus and
for so long as the delivery of a prospectus is required in connection with the Offering. The Company will advise the Placement Agent,
promptly after it receives notice thereof, (i) of any request by the Commission to amend the Registration Statement or to amend or supplement
any Prospectus or for additional information; (ii) of the issuance by the Commission of any stop order suspending the effectiveness of
the Registration Statement or any post-effective amendment thereto or any order preventing or suspending the use of the Preliminary Prospectus
or the Final Prospectus or any prospectus supplement or any amendment or supplement thereto, of the suspension of the qualification of
the Securities for offering or sale in any jurisdiction, or of the institution or threatened institution of any proceeding for any such
purpose; (iii) of the receipt of any comments or request for any additional information from the Commission; and (iv) of the happening
of any event during the period described in this Section 4(a) that, in the judgment of the Company, makes any statement of a material
fact made in the Registration Statement or the Prospectus untrue or that requires the making of any changes in the Registration Statement
or the Prospectus in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The
Company shall use its best efforts to prevent the issuance of any such stop order or prevention or suspension of such use. If the Commission
shall enter any such stop order at any time, the Company will use its best efforts to obtain the lifting of such order at the earliest
possible moment. Additionally, the Company agrees that it shall comply with the provisions of Rules 424(b), 430A, 430B and 430C, as applicable,
under the Securities Act, including with respect to the timely filing of documents thereunder, and will use its reasonable efforts to
confirm that any filings made by the Company under such Rule 424(b) are received in a timely manner by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) <B><I>Blue Sky Compliance. </I></B>The Company
will cooperate with the Placement Agent and the Investors in endeavoring to qualify the Securities for sale under the securities laws
of such jurisdictions (United States and foreign) as the Placement Agent and the Investors may reasonably request and will make such applications,
file such documents, and furnish such information as may be reasonably required for that purpose, provided the Company shall not be required
to qualify as a foreign corporation or to file a general consent to service of process in any jurisdiction where it is not now so qualified
or required to file such a consent, and provided further that the Company shall not be required to produce any new disclosure document.
The Company will advise the Placement Agent promptly of the suspension of the qualification or registration of (or any such exemption
relating to) the Securities for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such
purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use
its best efforts to obtain the withdrawal thereof at the earliest possible moment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) <B><I>Amendments and Supplements to a Prospectus
and Other Matters. </I></B>The Company will comply with the Securities Act and the Exchange Act, and the rules and regulations of the
Commission thereunder, so as to permit the completion of the distribution of the Securities as contemplated in this Agreement, the Incorporated
Documents and any Prospectus. If during the period in which a prospectus is required by law to be delivered in connection with the distribution
of Securities contemplated by the Incorporated Documents or any Prospectus (the &ldquo;Prospectus Delivery Period&rdquo;), any event shall
occur as a result of which, in the judgment of the Company or in the opinion of the Placement Agent or counsel for the Placement Agent,
it becomes necessary to amend or supplement the Incorporated Documents or any Prospectus in order to make the statements therein, in light
of the circumstances under which they were made, not misleading, or if it is necessary at any time to amend or supplement the Incorporated
Documents or any Prospectus to comply with any law, the Company will promptly prepare and file with the Commission, and furnish at its
own expense to the Placement Agent and to dealers, an appropriate amendment or supplement necessary in order to make the statements therein,
in light of the circumstances under which they were made, not misleading, or so that the Registration Statement, the Incorporated Documents
or any Prospectus, as so amended or supplemented, will comply with law. Before amending the Registration Statement or supplementing the
Incorporated Documents or any Prospectus in connection with the Offering, the Company will furnish the Placement Agent with a copy of
such proposed amendment or supplement and will not file any such amendment or supplement to which the Placement Agent reasonably objects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) <B><I>Copies of any Amendments and Supplements
to a Prospectus. </I></B>The Company will furnish the Placement Agent, without charge, during the period beginning on the date hereof
and ending on the later of the last Closing Date of the Offering, as many copies of any Prospectus or prospectus supplement and any amendments
and supplements thereto as the Placement Agent may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(e) <B><I>Free Writing Prospectus. </I></B>The
Company covenants that it will not, unless it obtains the prior written consent of the Placement Agent, make any offer relating to the
Securities that would constitute an issuer free writing prospectus or that would otherwise constitute a &ldquo;free writing prospectus&rdquo;
(as defined in Rule 405 of the Securities Act) required to be filed by the Company with the Commission or retained by the Company under
Rule 433 of the Securities Act. In the event that the Placement Agent expressly consents in writing to any such free writing prospectus
(a &ldquo;Permitted Free Writing Prospectus&rdquo;), the Company covenants that it shall (i) treat each Permitted Free Writing Prospectus
as an issuer free writing prospectus, and (ii) comply with the requirements of Rules 164 and 433 of the Securities Act applicable to such
Permitted Free Writing Prospectus, including in respect of timely filing with the Commission, legending and record keeping.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(f) <B><I>Transfer Agent. </I></B>The Company
will maintain, at its expense, a registrar and transfer agent for the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(g) <B><I>Earnings Statement. </I></B>As soon
as practicable and in accordance with applicable requirements under the Securities Act, but in any event not later than 18 months after
the last Closing Date, the Company will make generally available to its security holders and to the Placement Agent an earnings statement,
covering a period of at least 12 consecutive months beginning after the last Closing Date, that satisfies the provisions of Section 11(a)
and Rule 158 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(h) <B><I>Periodic Reporting Obligations. </I></B>During
the Prospectus Delivery Period, the Company will duly file, on a timely basis, with the Commission and the Trading Market all reports
and documents required to be filed under the Exchange Act within the time periods and in the manner required by the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) <B><I>Additional Documents. </I></B>The Company
will enter into any subscription, purchase or other customary agreements as the Placement Agent or the Investors deem necessary or appropriate
to consummate the Offering, all of which will be in form and substance reasonably acceptable to the Placement Agent and the Investors.
The Company agrees that the Placement Agent may rely upon, and is a third-party beneficiary of, the representations and warranties, and
applicable covenants, set forth in any such purchase, subscription or other agreement with Investors in the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(j) <B><I>No Manipulation of Price. </I></B>Neither
the Company, nor to its knowledge, any of its employees, directors or shareholders, has taken or will take, directly or indirectly, any
action designed to or that has constituted or that might reasonably be expected to cause or result in, under the Exchange Act or otherwise,
the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(k) <B><I>Acknowledgment. </I></B>The Company
acknowledges that any advice given by the Placement Agent to the Company is solely for the benefit and use of the Board of Directors of
the Company and may not be used, reproduced, disseminated, quoted or referred to, without the Placement Agent&rsquo;s prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(l) <B><I>Announcement of Offering. </I></B>The
Company acknowledges and agrees that the Placement Agent may, subsequent to the Closing, make public its involvement with the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(m) <B><I>Reliance on Others. </I></B>The Company
confirms that it will rely on its own counsel and accountants for legal and accounting advice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(n) <B><I>Research Matters. </I></B>By entering
into this Agreement, the Placement Agent does not provide any promise, either explicitly or implicitly, of favorable or continued research
coverage of the Company, and the Company hereby acknowledges and agrees that the Placement Agent&rsquo;s selection as a placement agent
for the Offering was in no way conditioned, explicitly or implicitly, on the Placement Agent providing favorable or any research coverage
of the Company. In accordance with FINRA Rule 2241(b)(2), the parties acknowledge and agree that the Placement Agent has not directly
or indirectly offered favorable research, a specific rating or a specific price target, or threatened to change research, a rating or
a price target, to the Company or as an inducement for the receipt of business or compensation. The Company hereby waives and releases,
to the fullest extent permitted by law, any claims that the Company may have against the Placement Agent with respect to any conflict
of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may
be different from or inconsistent with the views or advice communicated to the Company by the Placement Agent&rsquo;s investment banking
divisions. The Company acknowledges that the Placement Agent is a full-service securities firm and as such from time to time, subject
to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions
in debt or equity securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(o) <B><I>Subsequent Equity Sales. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i) From the date hereof until thirty
(30) days after the Closing Date, neither the Company nor any subsidiary shall (A) issue, enter into any agreement to issue or announce
the issuance or proposed issuance of any Common Stock or Common Stock Equivalents or (B) file any registration statement or amendment
or supplement thereto, other than the Prospectus or a registration statement on Form S-8 in connection with any employee benefit plan,
in each case without the prior written consent of the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ii) From the date hereof until six
(6) months after the Closing Date, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance
by the Company or any of its subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving a
Variable Rate Transaction. &ldquo;Variable Rate Transaction&rdquo; means a transaction in which the Company (A) issues or sells any debt
or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional shares of
Common Stock either (1) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the
trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities,
or (2) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of
such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of
the Company or the market for the Common Stock, or (B) enters into, or effects a transaction under, any agreement, including, but not
limited to, an equity line of credit or an &ldquo;at-the-market offering,&rdquo; whereby the Company may issue securities at a future
determined price. Any Investor shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which
remedy shall be in addition to any right to collect damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(iii) Notwithstanding the foregoing,
this Section 4(o) shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be an Exempt Issuance.
An &ldquo;Exempt Issuance&rdquo; means the issuance of (A) shares of Common Stock or options to employees, officers or directors of the
Company pursuant to any stock or option plan duly adopted for such purpose by a majority of the non-employee members of the Board of Directors
or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company;
(B) securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or
exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities
have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise, exchange
or conversion price of such securities (other than in connection with stock splits or combinations); (C) securities issued pursuant to
acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities
are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights that require or permit the
filing of any registration statement during the prohibition period in Section 4(o)(i), and provided that any such issuance shall be to
a Person (or to the equityholders of a Person) that is, itself or through its subsidiaries, an operating company or an owner of an asset
in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment
of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital
or to an entity whose primary business is investing in securities; and (D) securities issued to other Investors participating in the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(p) <B><I>Lock-Up Agreements. </I></B>The Placement
Agent is hereby designated as the sole lock-up release agent with respect to the Lock-Up Agreements, and the Company shall not amend,
modify, waive or terminate any provision of any of the Lock-Up Agreements except to extend the term of the lock-up period, and shall enforce
the provisions of each Lock-Up Agreement in accordance with its terms. If any party to a Lock-Up Agreement breaches any provision of a
Lock-Up Agreement, the Company shall promptly use its best efforts to seek specific performance of the terms of such Lock-Up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(q) <B><I>FINRA. </I></B>The Company shall advise
the Placement Agent (who shall make an appropriate filing with FINRA) if it is aware that any officer, director, or 10% or greater shareholder
of the Company, or any Person that received the Company&rsquo;s unregistered equity securities in the past 180 days, is or becomes an
affiliate or associated person of a FINRA member firm prior to the earlier of the termination of this Agreement or the 60-day period after
the effective date of the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 5. Conditions of the Obligations of
the Placement Agent. </B>The obligations of the Placement Agent hereunder shall be subject to the accuracy of the representations and
warranties on the part of the Company set forth in Section 2 hereof, in each case as of the date hereof and as of each Closing Date as
though then made, to the timely performance by the Company of its covenants and other obligations hereunder on and as of such dates, and
to each of the following additional conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) <B><I>Accountant&rsquo;s Comfort Letter. </I></B>On
the date hereof, the Placement Agent shall have received, and the Company shall have caused to be delivered to the Placement Agent, a
letter from Bush &amp; Associates CPA LLC addressed to the Placement Agent, dated as of the date hereof, in form and substance satisfactory
to the Placement Agent. The letter shall not disclose any change in the condition (financial or other), earnings, operations, business
or prospects of the Company from that set forth in the Incorporated Documents or the applicable Prospectus or prospectus supplement which,
in the Placement Agent&rsquo;s sole judgment, is material and adverse and that makes it, in the Placement Agent&rsquo;s sole judgment,
impracticable or inadvisable to proceed with the Offering of the Securities as contemplated by such Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) <B><I>Compliance with Registration Requirements;
No Stop Order; No Objection from FINRA. </I></B>Each Prospectus (in accordance with Rule 424(b)) and any free writing prospectus shall
have been duly filed with the Commission, as appropriate; no stop order suspending the effectiveness of the Registration Statement or
any part thereof shall have been issued and no proceeding for that purpose shall have been initiated or threatened by the Commission;
no order preventing or suspending the use of any Prospectus shall have been issued and no proceeding for that purpose shall have been
initiated or threatened by the Commission; all requests for additional information on the part of the Commission shall have been complied
with; and FINRA shall have raised no objection to the fairness and reasonableness of the placement terms and arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) <B><I>Corporate Proceedings. </I></B>All corporate
proceedings and other legal matters in connection with this Agreement, the Registration Statement and each Prospectus, and the registration,
sale and delivery of the Securities, shall have been completed or resolved in a manner reasonably satisfactory to the Placement Agent&rsquo;s
counsel, and such counsel shall have been furnished with such papers and information as it may reasonably have requested to enable such
counsel to pass upon the matters referred to in this Section 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) <B><I>No Material Adverse Change. </I></B>Subsequent
to the execution and delivery of this Agreement and prior to each Closing Date, in the Placement Agent&rsquo;s sole judgment after consultation
with the Company, there shall not have occurred any Material Adverse Effect or any material adverse change or development involving a
prospective material adverse change in the condition or the business activities, financial or otherwise, of the Company from the latest
dates as of which such condition is set forth in the Registration Statement and Prospectus (a &ldquo;Material Adverse Change&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(e) <B><I>Opinion of Counsel for the Company.
</I></B>The Placement Agent shall have received on each Closing Date the favorable opinion of Sichenzia Ross Ference Carmel LLP, counsel
to the Company, dated as of such Closing Date, including, without limitation, a negative assurance letter addressed to the Placement Agent,
in each case in form and substance satisfactory to the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(f) <B><I>Officers&rsquo; Certificate. </I></B>The
Placement Agent shall have received on each Closing Date a certificate of the Company, dated as of such Closing Date, signed by the Chief
Executive Officer and Chief Financial Officer of the Company, to the effect that, and the Placement Agent shall be satisfied that, the
signers of such certificate have reviewed the Registration Statement, the Incorporated Documents, the Prospectus and this Agreement, and
to the further effect that: (i) the representations and warranties of the Company in this Agreement are true and correct, as if made on
and as of such Closing Date, and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed
or satisfied at or prior to such Closing Date; (ii) no stop order suspending the effectiveness of the Registration Statement or the use
of the Prospectus has been issued and no proceedings for that purpose have been instituted or are pending or, to the Company&rsquo;s knowledge,
threatened under the Securities Act; and (iii) subsequent to the respective dates as of which information is given in the Registration
Statement, the Incorporated Documents and any Prospectus, there has not been any Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(g) <B><I>Regulatory Certificate. </I></B>On each
Closing Date, the Placement Agent shall have received a certificate from the Company&rsquo;s Chief Executive Officer with respect to certain
regulatory matters, dated as of the Closing Date, addressed to the Placement Agent in form and substance satisfactory to the Placement
Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(h) <B><I>Bring-down Comfort Letters. </I></B>On
each Closing Date, the Placement Agent shall have received from Bush &amp; Associates CPA LLC, or such other independent registered public
accounting firm of the Company, a letter dated as of such Closing Date, in form and substance satisfactory to the Placement Agent, to
the effect that they reaffirm the statements made in the letter furnished pursuant to subsection (a) of this Section 5, except that the
specified date referred to therein for the carrying out of procedures shall be no more than two business days prior to such Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) <B><I>Stock Exchange Listing. </I></B>The
Common Stock shall be registered under the Exchange Act and shall be listed on the Trading Market, and the Company shall not have taken
any action designed to terminate, or likely to have the effect of terminating, the registration of the Common Stock under the Exchange
Act or delisting or suspending from trading the Common Stock from the Trading Market, nor shall the Company have received any information
suggesting that the Commission or the Trading Market is contemplating terminating such registration or listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(j) <B><I>Lock-Up Agreements. </I></B>On or prior
to the date hereof, the Placement Agent shall have received the executed lock-up agreement, in the form attached to the Purchase Agreement
(each, a &ldquo;Lock-Up Agreement&rdquo;), from each of the Company&rsquo;s directors and executive officers and each shareholder holding
5% or more of the Company&rsquo;s outstanding Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(k) <B><I>Additional Documents. </I></B>On or
before each Closing Date, the Placement Agent and counsel for the Placement Agent shall have received such information and documents as
they may reasonably require for the purposes of enabling them to pass upon the issuance and sale of the Securities as contemplated herein,
or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements,
herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any condition specified in this Section 5 is
not satisfied when and as required to be satisfied, this Agreement may be terminated by the Placement Agent by notice to the Company at
any time on or prior to a Closing Date, which termination shall be without liability on the part of any party to any other party, except
that Section 6 (Payment of Expenses), Section 7 (Indemnification and Contribution) and Section 8 (Representations and Indemnities to Survive
Delivery) shall at all times be effective and shall survive such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 6. Payment of Expenses. </B>The Company
shall be responsible for and pay all expenses relating to the Offering, including, without limitation, all filing fees and communication
expenses relating to the registration of the Securities to be sold in the Offering with the Commission and the filing of the offering
materials with FINRA; all fees and expenses relating to the listing of such Securities on the Trading Market; all fees, expenses and disbursements
relating to background checks of the Company&rsquo;s officers and directors; all fees, expenses and disbursements relating to the registration
or qualification of such Securities under the &ldquo;blue sky&rdquo; securities laws of such states and other jurisdictions as the Placement
Agent may reasonably designate (including, without limitation, all filing and registration fees, and the fees and disbursements of the
Placement Agent&rsquo;s counsel at Closing); all fees and expenses associated with the i-Deal system and NetRoadshow not to exceed $3,000;
the costs of all mailing and printing of the Offering documents, Registration Statements, Prospectuses and all amendments, supplements
and exhibits thereto and as many preliminary and final Prospectuses as the Placement Agent may reasonably deem necessary; the costs of
preparing, printing and delivering certificates representing such Securities; fees and expenses of the transfer agent for such Securities;
stock transfer taxes, if any, payable upon the transfer of securities from the Company to the Placement Agent; and the fees and expenses
of the Company&rsquo;s accountants and the fees and expenses of the Company&rsquo;s legal counsel and other agents and representatives.
Upon the Placement Agent&rsquo;s request, the Company shall provide funds to pay all such fees, expenses and disbursements. For the sake
of clarity, it is understood and agreed that (i) the Company shall be responsible for the Placement Agent&rsquo;s legal fees, costs and
expenses in connection with the Offering irrespective of whether the Offering is consummated, and (ii) the legal fees, costs and expenses
incurred by the Placement Agent that the Company shall be responsible for shall be up to $80,000 (&ldquo;Reimbursable Expenses&rdquo;).
If the Offering is consummated, such Reimbursable Expenses shall be paid from, and deducted against, the gross proceeds of the Offering
at the Closing; if the Offering is not consummated, the Company shall pay such expenses directly to the Placement Agent and any such legal
expenses directly to Placement Agent Counsel, in each case promptly upon presentation of an invoice. The Placement Agent&rsquo;s legal
counsel shall be a third-party beneficiary of the expense reimbursement obligations set forth in this Section 6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 7. Indemnification and Contribution.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) The Company agrees to indemnify and hold harmless
the Placement Agent, its affiliates and each person controlling the Placement Agent (within the meaning of Section 15 of the Securities
Act), and the directors, officers, agents and employees of the Placement Agent, its affiliates and each such controlling person (the Placement
Agent, and each such entity or person, an &ldquo;Indemnified Person&rdquo;) from and against any losses, claims, damages, judgments, assessments,
costs and other liabilities (collectively, the &ldquo;Liabilities&rdquo;), and shall reimburse each Indemnified Person for all fees and
expenses (including the reasonable fees and expenses of one counsel for all Indemnified Persons, except as otherwise expressly provided
herein) (collectively, the &ldquo;Expenses&rdquo;) as they are incurred by an Indemnified Person in investigating, preparing, pursuing
or defending any actions, whether or not any Indemnified Person is a party thereto, (i) caused by, or arising out of or in connection
with, any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, any Incorporated Document,
or any Prospectus or by any omission or alleged omission to state therein a material fact necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading (other than untrue statements or alleged untrue statements in, or
omissions or alleged omissions from, information relating to an Indemnified Person furnished in writing by or on behalf of such Indemnified
Person expressly for use in the Registration Statement or any Prospectus) or (ii) otherwise arising out of or in connection with advice
or services rendered or to be rendered by any Indemnified Person pursuant to this Agreement, the transactions contemplated thereby or
any Indemnified Person&rsquo;s actions or inactions in connection with any such advice, services or transactions; provided, however, that,
in the case of clause (ii) only, the Company shall not be responsible for any Liabilities or Expenses of any Indemnified Person that are
finally judicially determined to have resulted solely from such Indemnified Person&rsquo;s (x) gross negligence or willful misconduct
in connection with any of the advice, actions, inactions or services referred to above or (y) use of any offering materials or information
concerning the Company in connection with the offer or sale of the Securities in the Offering which were not authorized for such use by
the Company and which use constitutes gross negligence or willful misconduct. The Company also agrees to reimburse each Indemnified Person
for all Expenses as they are incurred in connection with enforcing such Indemnified Person&rsquo;s rights under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Upon receipt by an Indemnified Person of actual
notice of an action against such Indemnified Person with respect to which indemnity may be sought under this Agreement, such Indemnified
Person shall promptly notify the Company in writing; provided that failure by any Indemnified Person so to notify the Company shall not
relieve the Company from any liability which the Company may have on account of this indemnity or otherwise to such Indemnified Person,
except to the extent the Company shall have been prejudiced by such failure. The Company shall, if requested by the Placement Agent, assume
the defense of any such action including the employment of counsel reasonably satisfactory to the Placement Agent, which counsel may also
be counsel to the Company. Any Indemnified Person shall have the right to employ separate counsel in any such action and participate in
the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless: (i) the Company
has failed promptly to assume the defense and employ counsel or (ii) the named parties to any such action (including any impleaded parties)
include such Indemnified Person and the Company, and such Indemnified Person shall have been advised in the reasonable opinion of counsel
that there is an actual conflict of interest that prevents the counsel selected by the Company from representing both the Company (or
another client of such counsel) and any Indemnified Person; provided that the Company shall not in such event be responsible hereunder
for the fees and expenses of more than one firm of separate counsel for all Indemnified Persons in connection with any action or related
actions, in addition to any local counsel. The Company shall not be liable for any settlement of any action effected without its written
consent (which shall not be unreasonably withheld). In addition, the Company shall not, without the prior written consent of the Placement
Agent (which shall not be unreasonably withheld), settle, compromise or consent to the entry of any judgment in or otherwise seek to terminate
any pending or threatened action in respect of which indemnification or contribution may be sought hereunder (whether or not such Indemnified
Person is a party thereto) unless such settlement, compromise, consent or termination includes an unconditional release of each Indemnified
Person from all Liabilities arising out of such action for which indemnification or contribution may be sought hereunder. The indemnification
required hereby shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as such expense,
loss, damage or liability is incurred and is due and payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) In the event that the foregoing indemnity
is unavailable to an Indemnified Person other than in accordance with this Agreement, the Company shall contribute to the Liabilities
and Expenses paid or payable by such Indemnified Person in such proportion as is appropriate to reflect (i) the relative benefits to the
Company, on the one hand, and to the Placement Agent and any other Indemnified Person, on the other hand, of the matters contemplated
by this Agreement or (ii) if the allocation provided by the immediately preceding clause is not permitted by applicable law, not only
such relative benefits but also the relative fault of the Company, on the one hand, and the Placement Agent and any other Indemnified
Person, on the other hand, in connection with the matters as to which such Liabilities or Expenses relate, as well as any other relevant
equitable considerations; provided that in no event shall the Company contribute less than the amount necessary to ensure that all Indemnified
Persons, in the aggregate, are not liable for any Liabilities and Expenses in excess of the amount of fees actually received by the Placement
Agent pursuant to this Agreement. For purposes of this paragraph, the relative benefits to the Company, on the one hand, and to the Placement
Agent on the other hand, of the matters contemplated by this Agreement shall be deemed to be in the same proportion as (a) the total value
paid or contemplated to be paid to or received or contemplated to be received by the Company in the transaction or transactions that are
within the scope of this Agreement, whether or not any such transaction is consummated, bears to (b) the fees paid to the Placement Agent
under this Agreement. Notwithstanding the above, no person guilty of fraudulent misrepresentation within the meaning of Section 11(f)
of the Securities Act shall be entitled to contribution from a party who was not guilty of fraudulent misrepresentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) The Company also agrees that no Indemnified
Person shall have any liability (whether direct or indirect, in contract or tort or otherwise) to the Company for or in connection with
advice or services rendered or to be rendered by any Indemnified Person pursuant to this Agreement, the transactions contemplated thereby
or any Indemnified Person&rsquo;s actions or inactions in connection with any such advice, services or transactions except for Liabilities
(and related Expenses) of the Company that are finally judicially determined to have resulted solely from such Indemnified Person&rsquo;s
gross negligence or willful misconduct in connection with any such advice, actions, inactions or services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(e) The reimbursement, indemnity and contribution
obligations of the Company set forth herein shall apply to any modification of this Agreement and shall remain in full force and effect
regardless of any termination of, or the completion of any Indemnified Person&rsquo;s services under or in connection with, this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 8. Representations and Indemnities
to Survive Delivery. </B>The respective indemnities, agreements, representations, warranties and other statements of the Company or any
person controlling the Company, of its officers, and of the Placement Agent set forth in or made pursuant to this Agreement will remain
in full force and effect, regardless of any investigation made by or on behalf of the Placement Agent, the Company, or any of its or their
partners, officers or directors or any controlling person, as the case may be, and will survive delivery of and payment for the Securities
sold hereunder and any termination of this Agreement. A successor to the Placement Agent, or to the Company, its directors or officers
or any person controlling the Company, shall be entitled to the benefits of the indemnity, contribution and reimbursement agreements contained
in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 9. Notices. </B>All communications
hereunder shall be in writing and shall be mailed, hand delivered, e-mailed or telecopied and confirmed to the parties hereto as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If to the Placement Agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">E.F. Hutton &amp; Co.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">745 Fifth Avenue, 34th Floor &amp; PH</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10151</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Anthony Salazar</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: asalazar@efhutton.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With a copy (which shall not constitute notice)
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zarif Law Group P.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">808 Springwood Avenue, Suite 110</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Asbury Park, NJ 07712</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Morris C. Zarif, Managing Partner</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: mzarif@zariflg.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">iSpecimen Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8 Cabot Road, Suite 1800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Woburn, MA 01801</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Katharyn Field, Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: [&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With a copy (which shall not constitute notice)
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sichenzia Ross Ference Carmel LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1185 Avenue of the Americas, 31st Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Ross D. Carmel, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: [&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any party hereto may change the address for receipt
of communications by giving written notice to the others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 10. Successors. </B>This Agreement
will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees, officers and directors and controlling
persons referred to in Section 7 hereof, and to their respective successors and personal representatives, and no other person will have
any right or obligation hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 11. Partial Unenforceability. </B>The
invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect the validity or enforceability
of any other section, paragraph or provision hereof. If any section, paragraph or provision of this Agreement is for any reason determined
to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to
make it valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 12. Governing Law. </B>This Agreement
will be governed by, and construed in accordance with, the laws of the State of New York applicable to agreements made and to be performed
entirely in such State, without regard to the conflicts of laws principles thereof. This Agreement may not be assigned by either party
without the prior written consent of the other party. This Agreement shall be binding upon and inure to the benefit of the parties hereto,
and their respective successors and permitted assigns. Any right to trial by jury with respect to any dispute arising under this Agreement
or any transaction or conduct in connection herewith is waived. Any dispute arising under this Agreement may be brought into the courts
of the State of New York or into the Federal court located in New York, New York, and, by execution and delivery of this Agreement, the
Company hereby accepts for itself and in respect of its property, generally and unconditionally, the jurisdiction of the aforesaid courts.
Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such suit, action
or proceeding by delivering a copy thereof via overnight delivery (with evidence of delivery) to such party at the address in effect for
notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.
Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. If either party
to this Agreement shall commence an action or proceeding to enforce any provisions of a Transaction Document, then the prevailing party
in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys&rsquo; fees and other costs and expenses
incurred in connection with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 13. General Provisions. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) This Agreement constitutes the entire agreement
of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and
negotiations with respect to the subject matter hereof. Notwithstanding anything herein to the contrary, that certain engagement letter,
dated April 14, 2026 (the &ldquo;Engagement Letter&rdquo;), between the Company and the Placement Agent shall continue to be effective
and the terms therein shall continue to survive and be enforceable by the Placement Agent in accordance with its terms (including, for
the avoidance of doubt, the provisions therein concerning the Definitive Agreement, Tail, line of credit flat fee (which the parties agree
shall survive termination of the Engagement Letter as though enumerated in Section 6 thereof), expense reimbursement, and indemnification),
provided that, in the event of a direct conflict between the terms of the Engagement Letter and this Agreement, the terms of this Agreement
shall prevail; provided, further, that nothing in this Agreement shall reduce, limit or supersede any role, Financing Fee (including any
allocation) or Reimbursable Expense payable to the Placement Agent under the Engagement Letter. This Agreement may be executed in two
or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the
same instrument. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein
(express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. Section headings herein
are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) The Company acknowledges that in connection
with the offering of the Securities: (i) the Placement Agent&rsquo;s responsibility to the Company is solely contractual and commercial
in nature, (ii) the Placement Agent has acted at arm&rsquo;s length, is not an agent of, and owes no fiduciary duties to the Company or
any other person, (iii) the Placement Agent owes the Company only those duties and obligations set forth in this Agreement and (iv) the
Placement Agent may have interests that differ from those of the Company. The Company waives to the fullest extent permitted by applicable
law any claims it may have against the Placement Agent arising from a breach or alleged breach of fiduciary duty in connection with the
offering of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Remainder of Page Intentionally Left Blank;
Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the foregoing is in accordance with your understanding
of our agreement, please sign below whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in
accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold">iSpecimen Inc.</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Name:</TD>
    <TD>Katharyn Field</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing Placement Agency Agreement is hereby
confirmed and accepted as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold">E.F. Hutton &amp; Co.</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="width: 35%"> Duncan B. Swanston</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Title:</TD>
    <TD> Supervisory Principal</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>ea030100601ex10-2.htm
<DESCRIPTION>FORM OF SECURITIES PURCHASE AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Securities Purchase Agreement (this &ldquo;Agreement&rdquo;)
is dated as of [*], 2026, between iSpecimen Inc., a Delaware corporation (the &ldquo;Company&rdquo;), and each purchaser identified on
the signature pages hereto (each, including its successors and assigns, a &ldquo;Purchaser&rdquo; and collectively the &ldquo;Purchasers&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, subject to the terms and conditions set
forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined below), the Company desires
to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of
the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOW, THEREFORE, IN CONSIDERATION of the mutual
covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged,
the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE I.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.1 <B><U>Definitions</U></B>. In addition to
the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in
this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Acquiring Person&rdquo;</B> shall have
the meaning ascribed to such term in Section 4.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Action&rdquo;</B> shall have the meaning
ascribed to such term in Section 3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Affiliate&rdquo;</B> means any Person
that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person
as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Board of Directors&rdquo;</B> means
the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Business Day&rdquo;</B> means any day
other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain
closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed
due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo; or any other similar orders or
restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic
funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally open for use by customers
on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Closing&rdquo;</B> means the closing
of the purchase and sale of the Securities pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Closing Date&rdquo;</B> means the Trading
Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent
to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s obligations to deliver the Securities,
in each case, have been satisfied or waived, but in no event later than the second (2nd) Trading Day following the effective date of the
Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Commission&rdquo;</B> means the United
States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Common Stock&rdquo;</B> means the common
stock of the Company, par value $0.0001 per share, and any other class of securities into which such securities may hereafter be reclassified
or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Common Stock Equivalents&rdquo;</B>
means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including,
without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable
or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Company Counsel&rdquo;</B> means Sichenzia
Ross Ference Carmel LLP, with offices located at 1185 Avenue of the Americas, 26th Floor, New York, New York 10036.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Disclosure Schedules&rdquo;</B> means
the Disclosure Schedules of the Company delivered concurrently herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Disclosure Time&rdquo;</B> means, (i)
if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight (New York City
time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof, unless otherwise instructed
as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight (New York City time) and 9:00 a.m.
(New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof, unless otherwise instructed
as to an earlier time by the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Evaluation Date&rdquo;</B> shall have
the meaning ascribed to such term in Section 3.1(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Exchange Act&rdquo;</B> means the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Exempt Issuance&rdquo;</B> means the
issuance of (a) shares of Common Stock or options to employees, officers, directors, service providers or vendors of the Company pursuant
to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority
of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, provided that
issuances to service providers or vendors of the Company pursuant to this clause (a) shall not exceed an aggregate value of $300,000 in
any calendar year, (b) shares of Common Stock to consultants, advisors, vendors or other service providers in exchange for services and
as approved by the Board of Directors, provided that such shares of Common Stock are issued as &ldquo;restricted securities&rdquo; (as
defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith
during the prohibition period in Section 4.12(a) herein, (c) warrants to the Placement Agent in connection with the transactions pursuant
to this Agreement and any shares of Common Stock upon exercise of the warrants to the Placement Agent, if applicable, and/or shares of
Common Stock upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or
exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities
have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange
price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such
securities, (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors
of the Company, provided that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no
registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition period
in Section 4.12(a) herein, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is,
itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company
and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which
the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in
securities, and (e) up to $[*] of Shares and Pre-Funded Warrants issued to other purchasers pursuant to the Prospectus concurrently with
the Closing at the Per Share Purchase Price, less the aggregate Subscription Amount pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;FCPA&rdquo;</B> means the Foreign Corrupt
Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;GAAP&rdquo;</B> shall have the meaning
ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Indebtedness&rdquo;</B> shall have the
meaning ascribed to such term in Section 3.1(bb).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Intellectual Property Rights&rdquo;</B>
shall have the meaning ascribed to such term in Section 3.1(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Legend Removal Date&rdquo;</B> shall
have the meaning ascribed to such term in Section 4.1(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Liens&rdquo;</B> means a lien, charge,
pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Lock-Up Agreement&rdquo;</B> means the
Lock-Up Agreement, dated as of the date hereof, by and among the Company and each of the directors and executive officers of the Company
and each holder of five percent (5%) or more of the Company&rsquo;s outstanding Common Stock, in the form of Exhibit B attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Material Adverse Effect&rdquo;</B> shall
have the meaning assigned to such term in Section 3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Material Permits&rdquo;</B> shall have
the meaning ascribed to such term in Section 3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Per Share Purchase Price&rdquo;</B>
equals $[*], subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions
of the Common Stock that occur after the date of this Agreement and prior to the Closing Date, provided that the purchase price per Pre-Funded
Warrant shall be the Per Share Purchase Price minus $0.0001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Person&rdquo;</B> means an individual
or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock
company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Placement Agent&rdquo;</B> means E.F.
Hutton &amp; Co.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Pre-Funded Warrants&rdquo;</B> means,
collectively, the pre-funded Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a)
hereof, which Pre-Funded Warrants shall be exercisable immediately and will expire when exercised in full, in the form of Exhibit A attached
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Pre-Funded Warrant Shares&rdquo;</B>
means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Proceeding&rdquo;</B> means an action,
claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition),
whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Preliminary Prospectus&rdquo;</B> means
any preliminary prospectus included in the Registration Statement, as originally filed or as part of any amendment thereto, or filed with
the Commission pursuant to Rule 424(a) of the rules and regulations of the Commission under the Securities Act, including all information,
documents and exhibits filed with or incorporated by reference into such preliminary prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Pricing Prospectus&rdquo;</B> means
(i) the Preliminary Prospectus relating to the Securities that was included in the Registration Statement immediately prior to [*] a.m./p.m.
(New York City time) on the date hereof and (ii) any free writing prospectus (as defined in the Securities Act) identified on Schedule
I hereto, taken together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Prospectus&rdquo;</B> means the final
prospectus filed for the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Purchaser Party&rdquo;</B> shall have
the meaning ascribed to such term in Section 4.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Registration Statement&rdquo;</B> means
the effective registration statement on Form S-1 (File No. 333-297001) which registers the sale of the Shares, the Pre-Funded Warrants
and the Pre-Funded Warrant Shares to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Release Date&rdquo;</B> means the Closing
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Required Approvals&rdquo;</B> shall
have the meaning ascribed to such term in Section 3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Rule 144&rdquo;</B> means Rule 144 promulgated
by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or
regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Rule 424&rdquo;</B> means Rule 424 promulgated
by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or
regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;SEC Reports&rdquo;</B> shall have the
meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Securities&rdquo;</B> means the Shares,
the Pre-Funded Warrants and the Pre-Funded Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Securities Act&rdquo;</B> means the
Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Shares&rdquo;</B> means the shares of
Common Stock issued or issuable to each Purchaser pursuant to this Agreement, but excluding the Pre-Funded Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Short Sales&rdquo;</B> means all &ldquo;short
sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include locating and/or borrowing
shares of Common Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Subscription Amount&rdquo;</B> means,
as to each Purchaser, the aggregate amount to be paid for Shares and Pre-Funded Warrants (if applicable) purchased hereunder as specified
below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo; in
United States dollars and in immediately available funds (excluding for the avoidance of doubt, if applicable, a Purchaser&rsquo;s aggregate
exercise price of the Pre-Funded Warrants, which amounts shall be paid as and when such Pre-Funded Warrants are exercised for cash).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Subsidiary&rdquo;</B> means any subsidiary
of the Company as set forth on Schedule 3.1(a) of the Disclosure Schedules, and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Trading Day&rdquo;</B> means a day on
which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Trading Market&rdquo;</B> means any
of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American,
the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors
to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Transaction Documents&rdquo;</B> means
this Agreement, the placement agency agreement, the Pre-Funded Warrants, the Lock-Up Agreement, all exhibits and schedules thereto and
hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Transfer Agent&rdquo;</B> means Broadridge
Corporate Issuer Solutions LLC, the current transfer agent of the Company, with a mailing address of 51 Mercedes Way, Edgewood, NY 11717,
and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Variable Rate Transaction&rdquo;</B>
shall have the meaning ascribed to such term in Section 4.12(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;ZLG&rdquo;</B> means Zarif Law Group
P.C., with offices located at 808 Springwood Avenue, Suite 110, Asbury Park, New Jersey 07712.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE II.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURCHASE AND SALE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.1 <B><U>Closing</U></B>. On the Closing Date,
upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers, severally and not jointly,
agree to purchase, up to an aggregate of $[*] of Shares; provided, however, that to the extent that a Purchaser determines, in its sole
discretion, that such Purchaser (together with such Purchaser&rsquo;s Affiliates, and any Person acting as a group together with such
Purchaser or any of such Purchaser&rsquo;s Affiliates) would beneficially own in excess of the Beneficial Ownership Limitation, or as
such Purchaser may otherwise choose, in lieu of purchasing Shares, such Purchaser may elect, by so indicating such election prior to their
issuance, to purchase Pre-Funded Warrants in lieu of Shares in such manner to result in the same aggregate purchase price being paid by
such Purchaser to the Company. The &ldquo;Beneficial Ownership Limitation&rdquo; shall be 4.99% (or, with respect to each Purchaser, at
the election of such Purchaser at Closing, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of the Shares on the Closing Date. In each case, the election to receive Pre-Funded Warrants is solely at the option of
the Purchaser. Each Purchaser&rsquo;s Subscription Amount as set forth on the signature page hereto executed by such Purchaser shall be
made available for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company or its designee. The Company shall deliver to each
Purchaser its respective Shares and Pre-Funded Warrants (if any), as determined pursuant to Section 2.2(a), and the Company and each Purchaser
shall deliver the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set
forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of Company Counsel or such other location (including remotely by
electronic transmission). Unless otherwise directed by the Placement Agent, settlement of the Shares shall occur via &ldquo;Delivery Versus
Payment&rdquo; (&ldquo;DVP&rdquo;) (i.e., on the Closing Date, the Company shall issue the Shares registered in the Purchasers&rsquo;
names and addresses and released by the Transfer Agent directly to the account(s) at the Placement Agent identified by each Purchaser;
upon receipt of such Shares, the Placement Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and the
applicable Purchaser shall deliver, or cause to be delivered, payment therefor through the Placement Agent (or its clearing firm) by wire
transfer to the Company or its designee). Each Purchaser acknowledges that, concurrently with the Closing and pursuant to the Prospectus,
the Company may sell up to $[*] of additional Shares and Pre-Funded Warrants to purchasers not party to this Agreement, less the aggregate
Subscription Amount pursuant to this Agreement, and will issue to such purchasers such shares of Common Stock or Pre-Funded Warrants in
the same form and at the same Per Share Purchase Price. Notwithstanding anything herein to the contrary, if at any time on or after the
time of execution of this Agreement by the Company and an applicable Purchaser, through, and including the time immediately prior to the
Closing (the &ldquo;Pre-Settlement Period&rdquo;), such Purchaser sells to any Person all, or any portion, of the Shares to be issued
hereunder to such Purchaser at the Closing (collectively, the &ldquo;Pre-Settlement Shares&rdquo;), such Purchaser shall, automatically
hereunder (without any additional required actions by such Purchaser or the Company), be deemed to be unconditionally bound to purchase,
and the Company shall be deemed unconditionally bound to sell, such Pre-Settlement Shares at the Closing; provided, that the Company shall
not be required to deliver any Pre-Settlement Shares to such Purchaser prior to the Company&rsquo;s receipt of the purchase price of such
Pre-Settlement Shares hereunder; and provided further that the Company hereby acknowledges and agrees that the foregoing shall not constitute
a representation or covenant by such Purchaser as to whether or not during the Pre-Settlement Period such Purchaser shall sell any shares
of Common Stock to any Person and that any such decision to sell any shares of Common Stock by such Purchaser shall solely be made at
the time such Purchaser elects to effect any such sale, if any. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise
(as defined in the Pre-Funded Warrants) delivered on or prior to 12:00 p.m. (New York City time) on the Closing Date, which may be delivered
at any time after the time of execution of this Agreement, the Company agrees to deliver the Pre-Funded Warrant Shares subject to such
notice(s) by 4:00 p.m. (New York City time) on the Closing Date and the Closing Date shall be the Warrant Share Delivery Date (as defined
in the Pre-Funded Warrants) for purposes thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.2 <B><U>Deliveries</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a) On or prior to the Closing Date
(except as indicated below), the Company shall deliver or cause to be delivered to each Purchaser the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">(i) this Agreement duly executed by
the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">(ii) a legal opinion of Company Counsel,
directed to the Placement Agent and the Purchasers, in form and substance reasonably acceptable to the Placement Agent and Purchasers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">(iii) a certificate of the Chief Financial
Officer of the Company regarding certain financial information included in the Registration Statement and Prospectus;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">(iv) subject to Section 2.1, the Company
shall have provided each Purchaser with the Company&rsquo;s wire instructions, on Company letterhead and executed by the Chief Executive
Officer or Chief Financial Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">(v) subject to Section 2.1, a copy
of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an expedited basis via The Depository
Trust Company Deposit or Withdrawal at Custodian system (&ldquo;DWAC&rdquo;) Shares equal to such Purchaser&rsquo;s Subscription Amount
divided by the Per Share Purchase Price (minus the number of shares of Common Stock issuable upon exercise of such Purchaser&rsquo;s Pre-Funded
Warrant, if applicable), registered in the name of such Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">(vi) if applicable, for each Purchaser
of Pre-Funded Warrants pursuant to Section 2.1, a Pre-Funded Warrant registered in the name of such Purchaser to purchase up to a number
of shares of Common Stock equal to the portion of such Purchaser&rsquo;s Subscription Amount applicable to Pre-Funded Warrants divided
by the Per Share Purchase Price minus $0.0001, with an exercise price equal to $0.0001 per share of Common Stock, subject to adjustment
therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">(vii) on the date hereof, the duly
executed Lock-Up Agreements; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">(viii) the Preliminary Prospectus and
the Prospectus (which may be delivered in accordance with Rule 172 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b) On or prior to the Closing Date,
each Purchaser shall deliver or cause to be delivered to the Company the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">(i) this Agreement duly executed by
such Purchaser; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">(ii) such Purchaser&rsquo;s Subscription
Amount (less the aggregate exercise price of the Pre-Funded Warrants issuable to such Purchaser hereunder, if applicable), which shall
be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company or its designee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.3 <B><U>Closing Conditions</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a) The obligations of the Company hereunder
in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">(i) the accuracy in all material respects
(or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and
on the Closing Date of the representations and warranties of the Purchasers contained herein (unless such representation or warranty is
as of a specific date therein in which case they shall be accurate in all material respects (or, to the extent representations or warranties
are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">(ii) all obligations, covenants and
agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed in all material respects;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">(iii) the delivery by each Purchaser
of the items set forth in Section 2.2(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b) The respective obligations of the
Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">(i) the accuracy in all material respects
(or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and
on the Closing Date of the representations and warranties of the Company contained herein (unless such representation or warranty is as
of a specific date therein in which case they shall be accurate in all material respects (or, to the extent representations or warranties
are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">(ii) all obligations, covenants and
agreements of the Company required to be performed at or prior to the Closing Date shall have been performed in all material respects;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">(iii) the delivery by the Company of
the items set forth in Section 2.2(a) of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">(iv) there shall have been no Material
Adverse Effect with respect to the Company; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">(v) from the date hereof to the Closing
Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s principal Trading Market, and,
at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or
limited, or minimum prices shall not have been established on securities whose trades are reported by such service, or on any Trading
Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have
occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect
on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser, makes it
impracticable or inadvisable to purchase the Securities at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE III.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPRESENTATIONS AND WARRANTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.1 <B><U>Representations and Warranties of the
Company</U></B>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part hereof and shall qualify
any representation made herein to the extent of the disclosure contained in the corresponding section of the Disclosure Schedules, the
Company hereby makes the following representations and warranties to each Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a) <B><U>Subsidiaries. </U></B>All
of the direct and indirect subsidiaries of the Company are set forth on Schedule 3.1(a). The Company owns, directly or indirectly, all
of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares
of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to
subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries or any of them in the
Transaction Documents shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b) <B><U>Organization and Qualification.
</U></B>The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties
and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of
any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents.
Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other
entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary,
except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result
in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect
on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken
as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material respect on a timely basis its
obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;Material Adverse Effect&rdquo;) and no Proceeding has
been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority
or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(c) <B><U>Authorization; Enforcement.
</U></B>The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this
Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution
and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions
contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is
required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith other than in
connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or upon delivery
will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the
valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general
equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting
enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive
relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(d) <B><U>No Conflicts. </U></B>The
execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the issuance
and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not (i) conflict
with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles of incorporation, bylaws or other
organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or
both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary,
or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation (with or without
notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or
otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or
any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule,
regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a
Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company
or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not, individually or in the
aggregate, have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(e) <B><U>Filings, Consents and Approvals.
</U></B>The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or
registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution,
delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant to Section 4.4 of
this Agreement, (ii) the filing with the Commission of the Prospectus, (iii) the notice and/or application(s) to each applicable Trading
Market for the issuance and sale of the Securities and the listing of the Shares and Pre-Funded Warrant Shares for trading thereon in
the time and manner required thereby, and (iv) such filings as are required to be made under applicable state securities laws (collectively,
the &ldquo;Required Approvals&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(f) <B><U>Issuance of the Securities;
Registration. </U></B>The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents,
will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Pre-Funded Warrant
Shares, when issued in accordance with the terms of the Pre-Funded Warrants, will be validly issued, fully paid and nonassessable, free
and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum number of shares
of Common Stock issuable pursuant to this Agreement and the Pre-Funded Warrants. The Company has prepared and filed the Registration Statement
in conformity with the requirements of the Securities Act, which became effective on [*], 2026, including the Prospectus, and such amendments
and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective under the Securities
Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of
any Preliminary Prospectus or the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted
or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and regulations of the Commission,
shall file the Prospectus with the Commission pursuant to Rule 424(b). At the time the Registration Statement and any amendments thereto
became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed
and will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading;
and the Pricing Prospectus and the Prospectus and any amendments or supplements thereto, at the time the Pricing Prospectus and the Prospectus
or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects to the
requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.
The Company was at the time of the filing of the Registration Statement eligible to use Form S-1 and is eligible to use Form S-1 on the
date hereof and on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(g) <B><U>Capitalization. </U></B>The
capitalization of the Company as of the date hereof is as set forth on Schedule 3.1(g), which Schedule 3.1(g) shall also include the number
of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date hereof. The Company has not issued
any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee
stock options under the Company&rsquo;s stock option plans, the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s
employee stock purchase plans, the issuance of share payments to vendors and/or independent service providers for services performed or
to be performed in the normal course of business, and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding
as of the date of the most recently filed periodic report under the Exchange Act. Other than the Placement Agent, no Person has any right
of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the
Transaction Documents. Except as a result of the purchase and sale of the Securities or as set forth on Schedule 3.1(g), there are no
outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities,
rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire,
any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which
the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital
stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common
Stock or other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company
or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon
an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary
that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the
Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any
stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement. All of the outstanding
shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance
with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar
rights to subscribe for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors or others
is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other similar agreements
with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among
any of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(h) <B><U>SEC Reports; Financial Statements.
</U></B>The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under
the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two (2) years preceding the date
hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including
the exhibits thereto and documents incorporated by reference therein, together with the Pricing Prospectus and the Prospectus, being collectively
referred to herein as the &ldquo;SEC Reports&rdquo;) on a timely basis or has received a valid extension of such time of filing and has
filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all
material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed,
contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company has never been
an issuer subject to Rule 144(i) under the Securities Act. The financial statements of the Company included in the SEC Reports comply
in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto
as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting
principles applied on a consistent basis during the periods involved (&ldquo;GAAP&rdquo;), except as may be otherwise specified in such
financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP,
and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the
dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to
normal, immaterial, year-end audit adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i) <B><U>Material Changes; Undisclosed
Events, Liabilities or Developments. </U></B>Since the date of the latest audited financial statements included within the SEC Reports,
except as set forth on Schedule 3.1(i), (i) there has been no event, occurrence or development that has had or that could reasonably be
expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than
(A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities
not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings made with the Commission,
(iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of
cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital
stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company
equity compensation plans. The Company does not have pending before the Commission any request for confidential treatment of information.
Except for the issuance of the Securities contemplated by this Agreement or as set forth on Schedule 3.1(i), no event, liability, fact,
circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company
or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required
to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been
publicly disclosed at least one (1) Trading Day prior to the date that this representation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(j) <B><U>Litigation. </U></B>Except
as set forth on Schedule 3.1(j), there is no material action, suit, inquiry, notice of violation, proceeding or investigation pending
or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties
before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an &ldquo;Action&rdquo;). None of the Actions set forth on Schedule 3.1(j), (i) adversely affects or challenges the legality,
validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision,
have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer
thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws
or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated,
any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission
has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary
under the Exchange Act or the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(k) <B><U>Labor Relations. </U></B>No
labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which could
reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo; employees is a member
of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the Company nor any of
its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships
with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected
to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement
or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued
employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any
of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and
regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the
failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(l) <B><U>Compliance. </U></B>Neither
the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with
notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary
received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other
agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation
has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii)
is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation
all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality
and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(m) <B><U>Environmental Laws. </U></B>The
Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution or protection
of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws
relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances
or wastes (collectively, &ldquo;Hazardous Materials&rdquo;) into the environment, or otherwise relating to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees,
demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations, issued,
entered, promulgated or approved thereunder (&ldquo;Environmental Laws&rdquo;); (ii) have received all permits, licenses or other approvals
required of them under applicable Environmental Laws to conduct their respective businesses; and (iii) are in compliance with all terms
and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably
expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(n) <B><U>Regulatory Permits. </U></B>The
Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign
regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except where the failure to possess
such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;Material Permits&rdquo;), and neither the
Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(o) <B><U>Title to Assets. </U></B>The
Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them, if any, and good and marketable
title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and
clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the
use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal, state
or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent
nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under
valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(p) <B><U>Intellectual Property. </U></B>The
Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service
marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary
or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to so have could
have a Material Adverse Effect (collectively, the &ldquo;Intellectual Property Rights&rdquo;). None of, and neither the Company nor any
Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been
abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement. Neither the Company
nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports, a written
notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person,
except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual
Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The
Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their
intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect. The Company has no knowledge of any facts that would preclude it from having valid license rights or clear title to the
Intellectual Property Rights. The Company has no knowledge that it lacks or will be unable to obtain any rights or licenses to use all
Intellectual Property Rights that are necessary to conduct its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(q) <B><U>Insurance. </U></B>The Company
and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts
as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited to, directors
and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company nor any Subsidiary has any reason
to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage
from similar insurers as may be necessary to continue its business without a significant increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(r) <B><U>Transactions With Affiliates
and Employees. </U></B>Except as set forth on Schedule 3.1(r), none of the officers or directors of the Company or any Subsidiary and,
to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the
Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement
providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing
of money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge
of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director,
trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for
services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock
option agreements under any stock option plan of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(s) <B><U>Sarbanes-Oxley; Internal Accounting
Controls. </U></B>The Company and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley Act
of 2002, as amended, that are effective as of the date hereof and as of the Closing Date, and any and all applicable rules and regulations
promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries
maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance
with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&rsquo;s
general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such
disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits
under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules
and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company
and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date,
the &ldquo;Evaluation Date&rdquo;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions
of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation
Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined
in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect,
the internal control over financial reporting of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(t) <B><U>Certain Fees. </U></B>Except
for compensation payable by the Company to the Placement Agent as set forth in the Pricing Prospectus and the Prospectus, no brokerage
or finder&rsquo;s fees or commissions are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant,
finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents.
The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for
fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(u) <B><U>Reserved. </U></B>Reserved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(v) <B><U>Investment Company. </U></B>The
Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate
of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct
its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration under the Investment Company
Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(w) <B><U>Registration Rights. </U></B>No
Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any securities of the
Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(x) <B><U>Listing and Maintenance Requirements.
</U></B>The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed
to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act
nor has the Company received any notification that the Commission is contemplating terminating such registration. Except as set forth
on Schedule 3.1(x), the Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which
the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements
of such Trading Market. Except as set forth on Schedule 3.1(x), the Company is, and has no reason to believe that it will not in the foreseeable
future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic
transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the
fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(y) <B><U>Application of Takeover Protections.
</U></B>The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share
acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision
under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws of its state of incorporation that is
or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising
their rights under the Transaction Documents, including without limitation as a result of the Company&rsquo;s issuance of the Securities
and the Purchasers&rsquo; ownership of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(z) <B><U>Disclosure. </U></B>Except
with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms
that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information
that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in the Pricing Prospectus
and the Prospectus. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions
in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and
its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement,
is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order
to make the statements made therein, in the light of the circumstances under which they were made, not misleading. The press releases
disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein,
in the light of the circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that no
Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically
set forth in Section 3.2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(aa) <B><U>No Integrated Offering. </U></B>Assuming
the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, neither the Company, nor any of its Affiliates,
nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers
to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the
Company for purposes of any applicable shareholder approval provisions of any Trading Market on which any of the securities of the Company
are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(bb) <B><U>Solvency. </U></B>Based on
the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company of the proceeds
from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds the amount that will be required
to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known contingent liabilities) as they
mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on its business as now conducted and as
proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted
by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the current cash flow of the
Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated
uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid.
The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts
of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe
that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from
the Closing Date. Schedule 3.1(bb) sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company
or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, &ldquo;Indebtedness&rdquo;
means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary
course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or
not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto), except guaranties by
endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the
present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither
the Company nor any Subsidiary is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(cc) <B><U>Tax Status. </U></B>Except
for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the
Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and franchise
tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental
assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations and (iii)
has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to
which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority
of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(dd) <B><U>Reserved. </U></B>Reserved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ee) <B><U>Foreign Corrupt Practices.
</U></B>Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person acting
on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment
or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government
officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully
any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which
is in violation of law, or (iv) violated in any material respect any provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ff) <B><U>Accountants. </U></B>The
Company&rsquo;s independent registered public accounting firm is Bush &amp; Associates CPA LLC. To the knowledge and belief of the Company,
such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) has expressed its opinion with
respect to the financial statements of the Company as of and for the fiscal years ended December 31, 2025 and December 31, 2024 included
(or incorporated by reference) in the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(gg) <B><U>No Disagreements with Accountants
and Lawyers. </U></B>There are no disagreements of any kind presently existing, or reasonably anticipated by the Company to arise, between
the Company and the accountants and lawyers formerly or presently employed by the Company and the Company is current with respect to any
fees owed to its accountants and lawyers which could affect the Company&rsquo;s ability to perform any of its obligations under any of
the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(hh) <B><U>Acknowledgment Regarding
Purchasers&rsquo; Purchase of Securities. </U></B>The Company acknowledges and agrees that each of the Purchasers is acting solely in
the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The
Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity)
with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their
respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely
incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions
contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ii) <B><U>Acknowledgment Regarding
Purchaser&rsquo;s Trading Activity. </U></B>Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for
Sections 3.2(f) and 4.14 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked by
the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company,
or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities for any specified term; (ii)
past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or &ldquo;derivative&rdquo;
transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of
the Company&rsquo;s publicly-traded securities; (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to which
any such Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the Common Stock, and (iv)
each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo;
transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various
times during the period that the Securities are outstanding, including, without limitation, during the periods that the value of the Pre-Funded
Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the
value of the existing stockholders&rsquo; equity interests in the Company at and after the time that the hedging activities are being
conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(jj) <B><U>Regulation M Compliance.
</U></B>The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed
to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale
of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities,
or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company,
other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the placement of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(kk) <B><U>Reserved. </U></B>Reserved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ll) <B><U>Reserved. </U></B>Reserved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(mm) <B><U>Stock Option Plans. </U></B>Each
stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance with the terms of the Company&rsquo;s
stock option plan and (ii) with an exercise price at least equal to the fair market value of the Common Stock on the date such stock option
would be considered granted under GAAP and applicable law. No stock option granted under the Company&rsquo;s stock option plan has been
backdated. The Company has not knowingly granted, and there is no and has been no Company policy or practice to knowingly grant, stock
options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material
information regarding the Company or its Subsidiaries or their financial results or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(nn) <B><U>Cybersecurity. </U></B>(i)(x)
There has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any Subsidiary&rsquo;s information
technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers,
vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &ldquo;IT Systems and Data&rdquo;)
and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition that would reasonably
be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries are
presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator
or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems
and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as
would not, individually or in the aggregate, have a Material Adverse Effect; (iii) the Company and the Subsidiaries have implemented and
maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, continuous
operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster
recovery technology consistent with industry standards and practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(oo) <B><U>Compliance with Data Privacy
Laws. </U></B>(i) The Company and the Subsidiaries are, and at all times during the last three (3) years were, in compliance with all
applicable state, federal and foreign data privacy and security laws and regulations, including, without limitation, the European Union
General Data Protection Regulation (&ldquo;GDPR&rdquo;) (EU 2016/679) (collectively, &ldquo;Privacy Laws&rdquo;); (ii) the Company and
the Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance with their policies and
procedures relating to data privacy and security and the collection, storage, use, disclosure, handling and analysis of Personal Data
(as defined below) (the &ldquo;Policies&rdquo;); (iii) the Company provides accurate notice of its applicable Policies to its customers,
employees, third party vendors and representatives as required by the Privacy Laws; and (iv) applicable Policies provide accurate and
sufficient notice of the Company&rsquo;s then-current privacy practices relating to its subject matter, and do not contain any material
omissions of the Company&rsquo;s then-current privacy practices, as required by Privacy Laws. &ldquo;Personal Data&rdquo; means (i) a
natural person&rsquo;s name, street address, telephone number, email address, photograph, social security number, bank information, or
customer or account number; (ii) any information which would qualify as &ldquo;personally identifying information&rdquo; under the Federal
Trade Commission Act, as amended; (iii) &ldquo;personal data&rdquo; as defined by GDPR; and (iv) any other piece of information that allows
the identification of such natural person, or his or her family, or permits the collection or analysis of any identifiable data related
to an identified person&rsquo;s health or sexual orientation. None of such disclosures made or contained in any of the Policies have been
inaccurate, misleading, or deceptive in violation of any Privacy Laws and the execution, delivery and performance of the Transaction Documents
will not result in a breach of any Privacy Laws or Policies. Neither the Company nor the Subsidiaries (i) to the knowledge of the Company,
has received written notice of any actual or potential liability of the Company or the Subsidiaries under, or actual or potential violation
by the Company or the Subsidiaries of, any of the Privacy Laws; (ii) is currently conducting or paying for, in whole or in part, any investigation,
remediation or other corrective action pursuant to any regulatory request or demand pursuant to any Privacy Law; or (iii) is a party to
any order, decree, or agreement by or with any court or arbitrator or governmental or regulatory authority that imposed any obligation
or liability under any Privacy Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(pp) <B><U>Office of Foreign Assets
Control. </U></B>Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director, officer, agent, employee
or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets
Control of the U.S. Treasury Department (&ldquo;OFAC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(qq) <B><U>U.S. Real Property Holding
Corporation. </U></B>The Company is not and has never been a U.S. real property holding corporation within the meaning of Section 897
of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(rr) <B><U>Bank Holding Company Act.
</U></B>Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as amended (the
&ldquo;BHCA&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;Federal Reserve&rdquo;). Neither
the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the outstanding
shares of any class of voting securities or twenty-five percent (25%) or more of the total equity of a bank or any entity that is subject
to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or Affiliates exercises a controlling
influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ss) <B><U>Money Laundering. </U></B>The
operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping
and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes
and applicable rules and regulations thereunder (collectively, the &ldquo;Money Laundering Laws&rdquo;), and no Action or Proceeding by
or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to
the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.2 <B><U>Representations and Warranties of the
Purchasers</U></B>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date hereof and as
of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate as of such date):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a) <B><U>Organization; Authority. </U></B>Such
Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws of the
jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and
authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations
hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the transactions
contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company
or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed
by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding
obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles
and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo;
rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies
and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b) <B><U>Understandings or Arrangements.
</U></B>Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement or understandings
with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty not limiting such
Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with applicable federal
and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(c) <B><U>Purchaser Status. </U></B>At
the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which it exercises any
Pre-Funded Warrants, it will be either: (i) an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7),
(a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act or (ii) a &ldquo;qualified institutional buyer&rdquo; as defined in Rule
144A(a) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(d) <B><U>Experience of Such Purchaser.
</U></B>Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience in business
and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has
so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the Securities
and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(e) <B><U>Access to Information. </U></B>Such
Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and schedules thereto)
and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers
from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of
investing in the Securities; (ii) access to information about the Company and its financial condition, results of operations, business,
properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional
information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment
decision with respect to the investment. Such Purchaser acknowledges and agrees that neither the Placement Agent nor any Affiliate of
the Placement Agent has provided such Purchaser with any information or advice with respect to the Securities nor is such information
or advice necessary or desired. Neither the Placement Agent nor any Affiliate has made or makes any representation as to the Company or
the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public information with respect to the Company
which such Purchaser agrees need not be provided to it. In connection with the issuance of the Securities to such Purchaser, neither the
Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(f) <B><U>Certain Transactions and Confidentiality.
</U></B>Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting on behalf of
or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short Sales, of
the securities of the Company during the period commencing as of the time that such Purchaser first received a term sheet (written or
oral) from the Company or any other Person representing the Company setting forth the material pricing terms of the transactions contemplated
hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed
investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets and the portfolio managers
have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&rsquo;s
assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that
made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement
or to such Purchaser&rsquo;s representatives, including, without limitation, its officers, directors, partners, legal and other advisors,
employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this
transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing
contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares
in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acknowledges and agrees that the representations
contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s right to rely on the Company&rsquo;s representations
and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other
document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated
hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty,
or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE IV.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OTHER AGREEMENTS OF THE PARTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.1 <B><U>Pre-Funded Warrant Shares</U></B>. If
all or any portion of a Pre-Funded Warrant is exercised at a time when there is an effective registration statement to cover the issuance
or resale of the Pre-Funded Warrant Shares or if the Pre-Funded Warrant is exercised via cashless exercise, the Pre-Funded Warrant Shares
issued pursuant to any such exercise shall be issued free of all legends. If at any time following the date hereof the Registration Statement
(or any subsequent registration statement registering the sale or resale of the Pre-Funded Warrant Shares) is not effective or is not
otherwise available for the sale or resale of the Pre-Funded Warrant Shares, the Company shall immediately notify the holders of the Pre-Funded
Warrants in writing that such registration statement is not then effective and thereafter shall promptly notify such holders when the
registration statement is effective again and available for the sale or resale of the Pre-Funded Warrant Shares (it being understood and
agreed that the foregoing shall not limit the ability of the Company to issue, or any Purchaser to sell, any of the Pre-Funded Warrant
Shares in compliance with applicable federal and state securities laws). The Company shall use best efforts to keep a registration statement
(including the Registration Statement) registering the issuance or resale of the Pre-Funded Warrant Shares effective during the term of
the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.2 <B><U>Furnishing of Information</U></B>. Until
the earlier of the time that (i) no Purchaser owns Securities or (ii) the Pre-Funded Warrants have expired, the Company covenants to maintain
the registration of the Common Stock under Section 12(b) or 12(g) of the Exchange Act and to timely file (or obtain extensions in respect
thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to
the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.3 <B><U>Integration</U></B>. The Company shall
not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities
Act) that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market
such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained
before the closing of such subsequent transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.4 <B><U>Securities Laws Disclosure; Publicity</U></B>.
The Company shall (a) by the Disclosure Time, issue a press release disclosing the material pricing terms of the transactions contemplated
hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto, with the Commission within
the time required by the Exchange Act. From and after the issuance of such press release, the Company represents to the Purchasers that
it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the Company or any of its
Subsidiaries, or any of their respective officers, directors, employees or agents in connection with the transactions contemplated by
the Transaction Documents. In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any
and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries
or any of their respective officers, directors, agents, employees or Affiliates on the one hand, and any of the Purchasers or any of their
Affiliates on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms that each Purchaser
shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and each Purchaser shall
consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company
nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company,
with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release
of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case
the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding
the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with
the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required
by federal securities law in connection with the filing of final Transaction Documents with the Commission and (b) to the extent such
disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice
of such disclosure permitted under this clause (b) and reasonably cooperate with such Purchaser regarding such disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.5 <B><U>Shareholder Rights Plan</U></B>. No
claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an &ldquo;Acquiring
Person&rdquo; under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger
the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement
between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.6 <B><U>Non-Public Information</U></B>. Except
with respect to the material pricing terms and conditions of the transactions contemplated by the Transaction Documents, which shall be
disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide
any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material
non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such information and agreed
in writing with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be relying
on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company, any of its Subsidiaries,
or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public information to a Purchaser
without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality
to the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates, or a duty to
the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates not to trade on the
basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent that
any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company
or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the Commission pursuant to
a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting
transactions in securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.7 <B><U>Use of Proceeds</U></B>. Except as set
forth on Schedule 4.7 attached hereto, the Company shall use the net proceeds from the sale of the Securities hereunder for working capital
purposes and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s debt (other than payment of trade
payables in the ordinary course of the Company&rsquo;s business and prior practices), (b) for the redemption of any Common Stock or Common
Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.8 <B><U>Indemnification of Purchasers</U></B>.
Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders,
members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities
Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other
Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of
such controlling persons (each, a &ldquo;Purchaser Party&rdquo;) harmless from any and all losses, liabilities, obligations, claims, contingencies,
damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&rsquo; fees and
costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations,
warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted
against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is
not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such
action is based upon a material breach of such Purchaser Party&rsquo;s representations, warranties or covenants under the Transaction
Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations by such Purchaser
Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially determined to constitute
fraud, gross negligence or willful misconduct). If any action shall be brought against any Purchaser Party in respect of which indemnity
may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have
the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party
shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of
such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically
authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ
counsel or (iii) in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the
position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees
and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y)
for any settlement by a Purchaser Party effected without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld
or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s
breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other
Transaction Documents. The indemnification required by this Section 4.8 shall be made by periodic payments of the amount thereof during
the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein
shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities
the Company may be subject to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.9 <B><U>Reservation of Common Stock</U></B>.
As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive
rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue Shares pursuant to this Agreement
and Pre-Funded Warrant Shares pursuant to any exercise of the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.10 <B><U>Listing of Common Stock</U></B>. The
Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock on the Trading Market on which it is
currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Shares and Pre-Funded Warrant
Shares on such Trading Market and promptly secure the listing of all of the Shares and Pre-Funded Warrant Shares on such Trading Market.
The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in
such application all of the Shares and Pre-Funded Warrant Shares, and will take such other action as is necessary to cause all of the
Shares and Pre-Funded Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then
take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all
respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company
agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established
clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established
clearing corporation in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.11 <B><U>[RESERVED]</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.12 <B><U>Subsequent Equity Sales</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a) From the date hereof until thirty
(30) days following the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce
the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or
any amendment or supplement thereto, other than (X) the Prospectus, (Y) filing a registration statement on Form S-8 in connection with
any employee compensation plan or (Z) the filing of any amendment or supplement to an existing registration statement for an &ldquo;at
the market&rdquo; offering with the Placement Agent as sales agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b) From the date hereof until the six
(6) month anniversary of the Closing Date, the Company shall be prohibited from effecting or entering into an agreement to effect any
issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving
a Variable Rate Transaction. &ldquo;Variable Rate Transaction&rdquo; means a transaction in which the Company (i) issues or sells any
debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional shares
of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with
the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities,
or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of
such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of
the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement whereby the Company
may issue securities at a future determined price, regardless of whether shares pursuant to such agreement have actually been issued and
regardless of whether such agreement is subsequently canceled; provided, however, that, following the expiration of the restrictive period
set forth in Section 4.12(a) above, (i) the entry into and/or issuance of shares of Common Stock in an &ldquo;at-the-market&rdquo; facility
with the Placement Agent as sales agent and/or (ii) the entry into and/or issuance of shares of Common Stock under an equity line of credit,
shall not be deemed a Variable Rate Transaction. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude
any such issuance, which remedy shall be in addition to any right to collect damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(c) Notwithstanding the foregoing, this
Section 4.12 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be an Exempt Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.13 <B><U>Equal Treatment of Purchasers</U></B>.
No consideration (including any modification of this Agreement) shall be offered or paid to any Person to amend or consent to a waiver
or modification of any provision of this Agreement unless the same consideration is also offered to all of the parties to this Agreement.
For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately
by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers
acting in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.14 <B><U>Certain Transactions and Confidentiality</U></B>.
Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it, nor any Affiliate acting on its behalf
or pursuant to any understanding with it will execute any purchases or sales, including Short Sales, of any of the Company&rsquo;s securities
during the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement
are first publicly announced pursuant to the initial press release as described in Section 4.4. Each Purchaser, severally and not jointly
with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by
the Company pursuant to the initial press release as described in Section 4.4, such Purchaser will maintain the confidentiality of the
existence and terms of this transaction and the information included in the Disclosure Schedules (other than as disclosed to its legal
and other representatives). Notwithstanding the foregoing and notwithstanding anything contained in this Agreement to the contrary, the
Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not
engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement
are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be restricted
or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and
after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release
as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the
Company to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agent, including,
without limitation, the Placement Agent after the issuance of the initial press release as described in Section 4.4. Notwithstanding the
foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions
of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio
managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect to the portion
of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.15 <B><U>Acknowledgment of Dilution</U></B>.
The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding shares of Common Stock, which dilution
may be substantial under certain market conditions. The Company further acknowledges that its obligations under the Transaction Documents,
including, without limitation, its obligation to issue the Shares and Pre-Funded Warrant Shares pursuant to the Transaction Documents,
are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of
any such dilution or any claim the Company may have against any Purchaser and regardless of the dilutive effect that such issuance may
have on the ownership of the other stockholders of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.16 <B><U>Exercise Procedures</U></B>. The form
of Notice of Exercise included in the Pre-Funded Warrants sets forth the totality of the procedures required of the Purchasers in order
to exercise the Pre-Funded Warrants. No additional legal opinion, other information or instructions shall be required of the Purchasers
to exercise their Pre-Funded Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required,
nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to
exercise the Pre-Funded Warrants. The Company shall honor exercises of the Pre-Funded Warrants and shall deliver Pre-Funded Warrant Shares
in accordance with the terms, conditions and time periods set forth in the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.17 <B><U>Capital Changes</U></B>. Until the
six (6) month anniversary of the Closing Date, the Company shall not undertake a reverse or forward stock split or reclassification of
the Common Stock without the prior written consent of the Purchasers holding a majority in interest of the Shares, other than a reverse
stock split that is required, in the good faith determination of the Board of Directors, to maintain the listing of the Common Stock on
the Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.18 <B><U>Lock-Up Agreements</U></B>. The Company
shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements except to extend the term of the lock-up period
and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. The Placement Agent shall be the sole lock-up
release agent for any Lock-Up Agreement. If any party to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company
shall promptly use its best efforts to seek specific performance of the terms of such Lock-Up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MISCELLANEOUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.1 <B><U>Termination</U></B>. This Agreement
may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect whatsoever on the obligations
between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been consummated on or before
the fifth (5th) Trading Day following the date hereof; provided, however, that no such termination will affect the right of any party
to sue for any breach by any other party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.2 <B><U>Fees and Expenses</U></B>. Except as
expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel,
accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution,
delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any fees required
for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered by a Purchaser), stamp taxes
and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.3 <B><U>Entire Agreement</U></B>. The Transaction
Documents, together with the exhibits and schedules thereto, the Pricing Prospectus and the Prospectus, contain the entire understanding
of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written,
with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.4 <B><U>Notices</U></B>. Any and all notices
or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and
effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via email attachment at the email
address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next
Trading Day after the time of transmission, if such notice or communication is delivered via email attachment at the email address as
set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any
Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service
or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall
be as set forth on the signature pages attached hereto. To the extent that any notice provided pursuant to any Transaction Document constitutes,
or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice
with the Commission pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.5 <B><U>Amendments; Waivers</U></B>. No provision
of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment,
by the Company and Purchasers which purchased at least 50.1% in interest of the Shares and the Pre-Funded Warrants based on the initial
Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by the party against
whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and
adversely impacts a Purchaser (or group of Purchasers), the consent of at least 50.1% in interest of such disproportionately impacted
Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement
of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner
impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the
rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior
written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon
each Purchaser and holder of Securities and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.6 <B><U>Headings</U></B>. The headings herein
are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.7 <B><U>Successors and Assigns</U></B>. This
Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not
assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger).
Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities,
provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction
Documents that apply to the &ldquo;Purchasers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.8 <B><U>No Third-Party Beneficiaries</U></B>.
The Placement Agent shall be the third party beneficiary of the representations, warranties, and covenants of the Company in this Agreement
and the representations, warranties, and covenants of the Purchasers in this Agreement. This Agreement is intended for the benefit of
the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be
enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.9 <B><U>Governing Law</U></B>. All questions
concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed
and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof.
Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated
by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors,
officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting
in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in
the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably
waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such
court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action
or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section
4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.10 <B><U>Survival</U></B>. The representations
and warranties contained herein shall survive the Closing and the delivery of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.11 <B><U>Execution</U></B>. This Agreement may
be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become
effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need
not sign the same counterpart. In the event that any signature is delivered by e-mail delivery (including any electronic signature covered
by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable
law, e.g., www.docusign.com) or other transmission method, such signature shall be deemed to have been duly and validly delivered and
shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force
and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.12 <B><U>Severability</U></B>. If any term,
provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable,
the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in
no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ
an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction.
It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions,
covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.13 <B><U>Rescission and Withdrawal Right</U></B>.
Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Documents,
whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not timely perform
its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from
time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its
future actions and rights; provided, however, that, in the case of a rescission of an exercise of a Pre-Funded Warrant, the applicable
Purchaser shall be required to return any shares of Common Stock subject to any such rescinded exercise notice concurrently with the return
to such Purchaser of the aggregate exercise price paid to the Company for such shares and the restoration of such Purchaser&rsquo;s right
to acquire such shares pursuant to such Purchaser&rsquo;s Pre-Funded Warrant (including, issuance of a replacement warrant certificate
evidencing such restored right).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.14 <B><U>Replacement of Securities</U></B>.
If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to
be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor,
a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction.
The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including
customary indemnity) associated with the issuance of such replacement Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.15 <B><U>Remedies</U></B>. In addition to being
entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company
will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate
compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive
and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.16 <B><U>Payment Set Aside</U></B>. To the extent
that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises
its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently
invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid
or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy
law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part
thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made
or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.17 <B><U>Independent Nature of Purchasers&rsquo;
Obligations and Rights</U></B>. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations
of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance of the obligations of
any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken
by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture
or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to
such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently protect
and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents,
and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose. Each Purchaser
has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative
convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through ZLG. ZLG does not represent
any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers with the same terms and
Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers.
It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between
the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.18 <B><U>Liquidated Damages</U></B>. The Company&rsquo;s
obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents is a continuing obligation of
the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have been paid notwithstanding the fact
that the instrument or security pursuant to which such partial liquidated damages or other amounts are due and payable shall have been
canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.19 <B><U>Saturdays, Sundays, Holidays, etc.</U></B>.
If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business
Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.20 <B><U>Construction</U></B>. The parties agree
that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore,
the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed
in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices and
shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends,
stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.21 <B><U>WAIVER OF JURY TRIAL</U>. IN ANY ACTION,
SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO
THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY
JURY.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, the parties hereto have caused
this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2"><B>ISPECIMEN INC.</B></TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%">&nbsp;</TD><TD STYLE="text-align: left; width: 35%">&nbsp;</TD><TD STYLE="text-align: justify; width: 60%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>By:</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>Name:</TD><TD STYLE="text-align: left">Katharyn Field</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>Title: </TD><TD STYLE="text-align: left">Chief Executive Officer</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address for Notice:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8 Cabot Road, Suite 1800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Woburn, MA 01801</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">E-Mail: _______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With a copy to (which shall not constitute notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sichenzia Ross Ference Carmel LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1185 Avenue of the Americas, 26th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, New York 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attn: Benjamin E. Sklar, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>SIGNATURE PAGE FOR PURCHASER FOLLOWS]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[PURCHASER SIGNATURE PAGES TO ISPECIMEN INC.
SECURITIES PURCHASE AGREEMENT]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, the undersigned have caused
this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Purchaser: ________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature of Authorized Signatory of Purchaser:
_________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: _______________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email Address of Authorized Signatory: _________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address for Notice to Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address for Delivery of Pre-Funded Warrants to
Purchaser (if not same as address for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subscription Amount: $_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pre-Funded Warrants: _______________ Beneficial
Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">EIN Number: _______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744; Notwithstanding anything contained in
this Agreement to the contrary, by checking this box (i) the obligations of the above-signed to purchase the securities set forth in this
Agreement to be purchased from the Company by the above-signed, and the obligations of the Company to sell such securities to the above-signed,
shall be unconditional and all conditions to Closing shall be disregarded, (ii) the Closing shall occur on the first (1st) Trading Day
following the date of this Agreement (or the second (2nd) Trading Day following the date of this Agreement if this Agreement is signed
on a day that is not a Trading Day or after 4:00 p.m. (New York City time) and before midnight (New York City time) on a Trading Day)
and (iii) any condition to Closing contemplated by this Agreement (but prior to being disregarded by clause (i) above) that required delivery
by the Company or the above-signed of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer
be a condition and shall instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement,
instrument, certificate or the like or purchase price (as applicable) to such other party on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[SIGNATURE PAGES CONTINUE]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Free Writing Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF PRE-FUNDED WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LOCK-UP AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[_______], 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">iSpecimen Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8 Cabot Rd., Suite 1800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Woburn, MA 01801</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Re: </I>Placement Agency Agreement, dated as
of [_______], 2026 (the &ldquo;Placement Agency Agreement&rdquo;), between iSpecimen Inc. (the &ldquo;Company&rdquo;) and E.F. Hutton
&amp; Co. (the &ldquo;Placement Agent&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Defined terms not otherwise
defined in this letter agreement (the &ldquo;Letter Agreement&rdquo;) shall have the meanings set forth in the Placement Agency Agreement.
In satisfaction of a condition of the Company&rsquo;s obligations under the Placement Agency Agreement, the undersigned irrevocably agrees
with the Company that, from the date hereof until the date that is ninety (90) days following the Closing Date (such period, the &ldquo;<B>Restriction
Period</B>&rdquo;), the undersigned will not offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of (or enter into
any transaction which is designed to, or might reasonably be expected to, result in the disposition (whether by actual disposition or
effective economic disposition due to cash settlement or otherwise) by the undersigned or any Affiliate of the undersigned to the extent
such Affiliate transaction would be required to be reported by the undersigned during the Restriction Period with the Securities and Exchange
Commission in accordance with Section 13 or Section 16 of the Exchange Act), directly or indirectly, or establish or increase a put equivalent
position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Securities Exchange Act of 1934,
as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), with respect to, any shares of Common Stock of the Company or securities convertible,
exchangeable or exercisable into, shares of Common Stock of the Company beneficially owned, held or hereafter acquired by the undersigned
(the &ldquo;<B>Securities</B>&rdquo;), other than Securities acquired in the Offering, or make any demand for or exercise any right or
cause to be filed a registration, including any amendments thereto, with respect to the registration of any shares of Common Stock or
Common Stock Equivalents or publicly disclose the intention to do any of the foregoing. Beneficial ownership shall be calculated in accordance
with Section 13(d) of the Exchange Act. The undersigned acknowledges that the Company shall provide written notice to the transfer agent
of the Company to inform them of the Restriction Period, which written notice shall include notification by email. In order to enforce
this covenant, the Company shall impose irrevocable stop-transfer instructions preventing the transfer agent of the Company from effecting
any actions in violation of this Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Placement Agent shall
serve as the sole lock-up release agent for the Restriction Period. No release of any obligation under this Letter Agreement shall be
effective without the prior written consent of the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
and subject to the conditions below, the undersigned may transfer the Securities provided that (1) the Company receives a signed lock-up
letter agreement (in the form of this Letter Agreement) for the balance of the Restriction Period from each donee, trustee, distributee,
or transferee, as the case may be, prior to such transfer (2) any such transfer shall not involve a disposition for value, (3) such transfer
is not required to be reported with the Securities and Exchange Commission in accordance with the Exchange Act and no report of such transfer
shall be made voluntarily during the Restricted Period, and (4) neither the undersigned nor any donee, trustee, distributee or transferee,
as the case may be, otherwise voluntarily effects any public filing or report regarding such transfers during the Restricted Period, with
respect to transfer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in; text-align: left">(i)</TD><TD STYLE="text-align: justify">as a bona fide gift or gifts;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">to any immediate family member or to any trust for the direct
or indirect benefit of the undersigned or the immediate family of the undersigned (for purposes of this Letter Agreement, &ldquo;immediate
family&rdquo; shall mean any relationship by blood, marriage or adoption, not more remote than first cousin);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">to any corporation, partnership, limited liability company,
or other business entity all of the equity holders of which consist of the undersigned and/or the immediate family of the undersigned;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">if the undersigned is a corporation, partnership, limited liability
company, trust or other business entity (a) to another corporation, partnership, limited liability company, trust or other business entity
that is an Affiliate of the undersigned or (b) in the form of a distribution to limited partners, limited liability company members or
stockholders of the undersigned;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in; text-align: left">(v)</TD><TD STYLE="text-align: justify">if the undersigned is a trust, to the beneficiary of such trust;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in; text-align: left">(vi)</TD><TD STYLE="text-align: justify">by operation of law, such as pursuant to a qualified domestic
order, divorce settlement, divorce decree, separation agreement or other court order;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in; text-align: left">(vii)</TD><TD STYLE="text-align: justify">to a charity or educational institution;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in; text-align: left">(viii)</TD><TD STYLE="text-align: justify">by will, other testamentary document or intestate succession
to the legal representative, heir, beneficiary or a member of the immediate family of the undersigned; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.3in; text-align: left">(ix)</TD><TD STYLE="text-align: justify">sales of Common Stock made pursuant to and in accordance with
a trading plan pursuant to Rule 10b5-1 under the Exchange Act existing on the date hereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, notwithstanding
the foregoing, this Letter Agreement shall not restrict (i) the delivery of shares of Common Stock to the undersigned upon exercise of
any options or settlement of restricted stock units or other equity awards granted under any employee benefit plan of the Company, or
the exercise of warrants; provided in each case that any shares of Common Stock or Securities acquired in connection with any such exercise
or settlement will be subject to the restrictions set forth in this Letter Agreement, (ii) the withholding of shares of Common Stock to
cover the payment of the exercise prices or the payment of taxes associated with the exercise or settlement of equity set forth in (i)
above, or (iii) the issuance to the undersigned of awards by the Company under its equity incentive plans or the issuance of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, the undersigned
may enter into any new plan established in compliance with Rule 10b5-1 of the Exchange Act; provided that (i) such plan may only be established
if no public announcement or filing with the Securities and Exchange Commission, or other applicable regulatory authority, is made in
connection with the establishment of such plan during the Restriction Period and (ii) no sale of shares of Common Stock are made pursuant
to such plan during the Restriction Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned acknowledges
that the execution, delivery and performance of this Letter Agreement is a material inducement to the Placement Agent to complete the
transactions contemplated by the Placement Agency Agreement and the Company shall be entitled to specific performance of the undersigned&rsquo;s
obligations hereunder. The undersigned hereby represents that the undersigned has the power and authority to execute, deliver and perform
this Letter Agreement, that the undersigned has received adequate consideration therefor and that the undersigned will indirectly benefit
from the closing of the transactions contemplated by the Placement Agency Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned understands
that, if the Placement Agency Agreement does not become effective, or if the Placement Agency Agreement (other than the provisions thereof
which survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold thereunder,
the undersigned shall be released from all obligations under this Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Letter Agreement may
not be amended or otherwise modified in any respect without the written consent of each of the Company and the undersigned. This Letter
Agreement shall be construed and enforced in accordance with the laws of the State of New York without regard to the principles of conflict
of laws. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. The undersigned
agrees and understands that this Letter Agreement does not intend to create any relationship between the undersigned and the Placement
Agent and that the Placement Agent is not entitled to cast any votes on the matters herein contemplated and that no issuance or sale of
the Securities is created or intended by virtue of this Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Letter Agreement shall
be binding on successors and assigns of the undersigned with respect to the Securities and any such successor or assign shall enter into
a similar agreement for the benefit of the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>*** SIGNATURE PAGE FOLLOWS***</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGE TO THE LOCK-UP AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Letter Agreement may
be executed in two or more counterparts, all of which when taken together may be considered one and the same agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Print Name</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title / Position (if any)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address for Notice:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By signing below, the Company
agrees to enforce the restrictions on transfer set forth in this Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-weight: bold">iSpecimen Inc.</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="width: 32%">Katharyn Field</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 33; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>ea030100601ex99-1.htm
<DESCRIPTION>PRESS RELEASE DATED AUGUST 6, 2026, ANNOUNCING THE PRICING OF THE OFFERING
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>iSpecimen Inc. Announces Pricing of $5 Million Public Offering of
Common Stock and Pre-Funded Warrants</B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><B>WOBURN, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) --&nbsp;</B>iSpecimen
Inc. (Nasdaq: ISPC) (&ldquo;iSpecimen&rdquo; or the &ldquo;Company&rdquo;), an online global marketplace that connects scientists requiring
biospecimens for medical research with a network of healthcare specimen providers, announced today the pricing of its public offering
of approximately $5 million of the Company&rsquo;s common stock, and/or pre-funded warrants to purchase shares of common stock at a public
offering price of $1.30 per share (or $1.2999 per pre-funded warrant, which is equal to the public offering price per share minus the
$0.0001 per share exercise price of each pre-funded warrant). The Company intends to use the proceeds of the offering for repayment of
outstanding liabilities, potential acquisitions of assets or investments in businesses, products and technologies and for marketing and
advertising services. The remainder of proceeds will be used for working capital purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">E.F. Hutton &amp; Co. is acting as the exclusive placement agent in
connection with the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The offering is expected to close on August 7, 2026, subject to customary
closing conditions. The securities described above are being offered pursuant to the Company&rsquo;s registration statement on Form S-1
(File No. 333-297001) (the &ldquo;Registration Statement&rdquo;), initially filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;)
on June 24, 2026, and subsequently declared effective by the SEC on July 30, 2026. The offering is being made only by means of a prospectus
which is a part of the Registration Statement. A preliminary prospectus relating to the offering has been filed with the&nbsp;SEC. A final
prospectus relating to the offering will be filed with the SEC and will be available on the SEC&rsquo;s website at&nbsp;https://www.sec.gov/.
Copies of the final prospectus relating to this offering, when available, may be obtained from E.F. Hutton &amp; Co., 745 Fifth Avenue,
34th Floor &amp; PH, New York, NY 10151.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release shall not constitute an offer to sell or a solicitation
of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any
such state or other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About iSpecimen</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens,
connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens
needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients
across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information,
please visit&nbsp;www.ispecimen.com<U>.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release may contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Such forward-looking statements are characterized by future or conditional verbs such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo;
&ldquo;intend,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue&rdquo; or similar words.
You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections
of future results of operations or financial condition or state other forward-looking information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Forward-looking statements are predictions, projections and other statements
about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many
factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but
not limited to the risk factors contained in the Company&rsquo;s filings with the U.S. Securities and Exchange Commission, which are available
for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over
time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and
circumstances reflected in the Company&rsquo;s forward-looking statements occurs, the Company&rsquo;s business, financial condition and
operating results may vary materially from those expressed in the Company&rsquo;s forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Readers are cautioned not to put undue reliance on forward-looking
statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as
a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">info@ispecimen.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>6
<FILENAME>ea030100601ex99-2.htm
<DESCRIPTION>PRESS RELEASE DATED AUGUST 7, 2026, ANNOUNCING THE CLOSING OF THE OFFERING
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>iSpecimen Inc. Announces Closing of $5 Million
Public Offering of Common Stock and Pre-Funded Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WOBURN, Mass., Aug. 07, 2026 (GLOBE
NEWSWIRE) --</B> <U></U> iSpecimen Inc. (Nasdaq: ISPC) (&ldquo;iSpecimen&rdquo; or the &ldquo;Company&rdquo;), an
online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen
providers, announced today the closing of its previously announced public offering of an aggregate of 996,231 shares of the Company&rsquo;s common stock and pre-funded warrants to purchase up to an aggregate of 2,849,923
shares of common stock, for an aggregate purchase price of approximately $5.0 million. The Company intends to use the proceeds of the offering for repayment of outstanding liabilities,
potential acquisitions of assets or investments in businesses, products and technologies and for marketing and advertising services.
The remainder of the proceeds will be used for working capital purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">E.F. Hutton &amp; Co. is acting as the exclusive
placement agent in connection with the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities described above are being offered
pursuant to the Company&rsquo;s registration statement on Form S-1 (File No. 333-297001) (the &ldquo;Registration Statement&rdquo;), initially
filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on June 24, 2026, and subsequently declared effective by the
SEC on July 30, 2026. The offering is being made only by means of a prospectus which is a part of the Registration Statement. A final
prospectus relating to the offering has been filed with the SEC and is available on the SEC&rsquo;s website at https://www.sec.gov/.
Copies of the final prospectus relating to this offering may be obtained from E.F. Hutton &amp; Co., 745 Fifth Avenue, 34th Floor &amp;
PH, New York, NY 10151.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release shall not constitute an offer
to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in
any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About iSpecimen</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">iSpecimen (Nasdaq: ISPC) offers an online marketplace
for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to
patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for
specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations.
For more information, please visit <U>www.ispecimen.com.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cautionary Note Regarding Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains &ldquo;forward-looking
statements&rdquo; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements other than statements
of historical fact and may be identified by the use of words or expressions such as &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo;
&ldquo;would,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;believe,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;seek,&rdquo; &ldquo;potential,&rdquo; &ldquo;target,&rdquo; &ldquo;project,&rdquo;
&ldquo;forecast,&rdquo; &ldquo;outlook,&rdquo; or similar expressions, or by discussions of strategy, plans, or intentions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements in this press release
include, but are not limited to, statements regarding the anticipated use of proceeds from the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including,
among others, risks and uncertainties associated with market conditions, the Company&rsquo;s ability to deploy the proceeds of the offering
as anticipated, the Company&rsquo;s ability to maintain compliance with the continued listing standards of The Nasdaq Capital Market,
and the other risks and uncertainties described in the &ldquo;Risk Factors&rdquo; sections of the Company&rsquo;s Annual Report on Form
10-K for the year ended December 31, 2025, filed with the SEC on April 1, 2026, and of the Registration Statement and the final prospectus
relating to the offering, as well as in the Company&rsquo;s other filings with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The forward-looking statements in this press release
speak only as of the date of this press release. Except as required by applicable law, the Company undertakes no obligation to publicly
update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">info@ispecimen.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ispc-20260805.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qpZs7xRiXgen8uBYXYsWaiKWaPtyJ1x+YkxuG99fYnabyMtc8QBtyvM91kGIdcI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:srt-types="http://fasb.org/srt-types/2026" xmlns:ISPC="http://ispecimen.com/20260805" elementFormDefault="qualified" targetNamespace="http://ispecimen.com/20260805">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://ispecimen.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="ispc-20260805_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ispc-20260805_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2026" schemaLocation="https://xbrl.sec.gov/dei/2026/dei-2026.xsd" />
    <import namespace="http://fasb.org/us-gaap/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd" />
    <import namespace="http://fasb.org/us-types/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2026" schemaLocation="https://xbrl.sec.gov/country/2026/country-2026.xsd" />
    <import namespace="http://fasb.org/srt/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd" />
    <import namespace="http://fasb.org/srt-types/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>ispc-20260805_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ispc-20260805_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="ispc-20260805.xsd#Cover" roleURI="http://ispecimen.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://ispecimen.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 05, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  05,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">iSpecimen
Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001558569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-0480143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8 Cabot
    Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Woburn<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">01801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">301-6700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ISPC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ea0301006-8k_ispecimen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ispecimen.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0301006-8k_ispecimen.htm">ea0301006-8k_ispecimen.htm</File>
    <File>ispc-20260805.xsd</File>
    <File>ispc-20260805_lab.xml</File>
    <File>ispc-20260805_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0301006-8k_ispecimen.htm": {
   "nsprefix": "ISPC",
   "nsuri": "http://ispecimen.com/20260805",
   "dts": {
    "inline": {
     "local": [
      "ea0301006-8k_ispecimen.htm"
     ]
    },
    "schema": {
     "local": [
      "ispc-20260805.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd",
      "https://xbrl.sec.gov/country/2026/country-2026.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
      "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ispc-20260805_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ispc-20260805_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2026": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2026": 24
   },
   "report": {
    "R1": {
     "role": "http://ispecimen.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2026-08-05",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0301006-8k_ispecimen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-08-05",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0301006-8k_ispecimen.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CountryRegion",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentType",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Extension",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12gTitle",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ispecimen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001213900-26-086768-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-26-086768-xbrl.zip
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MQ3L&T@+8P[\R8*'"?[>NT_Y=C^H.>P:DXQ"DF@%<F%8 E$WUAJ&RR7LVO9/
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M&N-^_N+5VU.WL\G7]N#DY/C@[/#@P>'!*7G+,+P\-?O0D6W3/][J@Q75*?O
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MIZ O;N]>^B?<WMOW=U]]A,W]\#"(.B9VM]W5CF$&]AX5+57:Z])55$-E0(Q
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M"S/0 "A-N!OI"5.[0AHE*E]#MVX1[FU<^31(.%?"3=\_*;/GBM-KBA/<'$Q
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M$+D[)G6$L</C4"2C,J+K1K#SDOMY[P( FH@K$@^;QF'OBMK1'"OC7JHSK!K
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M(B :;H0;ELK, X"JI@[ ,2G74B>X&OJR7LJ"VUP/JL+58=%TC&F=P?IW!-/
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M86$ZGE+[64$!(+W(,,A2!(8\AC+(VOGFVX</L^)T?9K-G XD?Q]OO1.RJ_B
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MKOY3%^6.K+Y=!EV I]G[W0;F>=X5\VKQ-'L-!B4OTNL6I_XHR,#KK_"3S^B
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M%H3EP@B%%9:4D)!H^' O+AVOBUDU%(%^) 5,(H<6,DAU%N\R#O?X2.1//<)
M0"I+T"P\5S)H]VJW1](D&G><U#\[^-4@=S:YD?^P9R9K2J2<0Z(0!.&2L<,<
MYW2_%U6-[^-@:]^:%:#+))PI<5#Q;=)K>R\,[2+;G0M4M)TM\J)6[1M7/,9\
M;XC#^#:;4<'3R+F6>GW)2%!Q&BR=G$@)O9=8SK0HP=.IQ9F7<,9(E^;2D7;J
M/2[UP2,CV</5U;@UGZ;<[43N>MGV3+X@V:ULYJ, 5J><W$?^I*$M808*#.74
M'*;1HK [UBB.?>FR8'" @^ 4 K>1#(U3HI:E(!AN%96O5)B8LIE!Z0PQL;[9
M3 X[[*:LM0X<RPP$M#61*G$E+<Q$F?D>ZGC9(A"L;*@>A^@OECH+$O+@"&&!
MSP<24 JH$7EYARIN$)YBC#65Y0?IF4Q?+^7+YIO"_#/6N[ B77BL#ODV7NAM
M?,[S9S7[-+O@4T>)\O1-?"WZP5]B[JJ=NL[(9^5NX'IE@=1MUVM)_>WA^*:@
M(T)MPD8CUA3@VR)M9)&1ZNY^?U=N![JG[!DP'5*:H-\86>..38,O8)=O2?=!
MN>_P$HQ,[.+)ZN"W6?7+P^Q"'1^-V-#G.S_X^<[&<O'FDSWY)R\K19[UWLB4
MS(^UC7:LCP<'YU?Y;^0'N#4NG1=.ARM#OFO!LL5G/2>?I>WZJ7 ^>0N@%Y<(
M3 CA"#@?;3<_^'^('5,TQ,65@B^,V\?B=D[LU^1&,<,.7M\5=:@HA*T,CP(M
M+]*X466<RL7Q$=&-N0TX&6&4X[7-.5V_MP2$)( (A$VX8= Z''JC9Q)BWX-N
M5/K>O&)+QLM\O,/NQD5?ZZI I1Q\GA@1'B(:49Z)W4$W?I])T@,G*ID4L$S0
M$:6G2^9&F_Z9FB_,2'3;S;! SK.F;^L;;%J I8*A+6TR%NZ,._M<WJC/94>#
MVUNC05]Z'8??7G18V]DZ1D1U(ET&2.V+8%;TKJY$ZY@O',*#,)K962P.Y"!W
M-)/J5LT/VV;!);Y8*E2N(F>=5J+#\%(E*\16 B[(JNB$):)<-]X"%-+- 1S>
MK7#Z.J-<JHO,X,V"PSP.^9Y;ZCWWND7,] JF/9@PSOOK4LO62*R<7B?.+[]I
MX[QZ2NW?I>[3:B1W415\$]\O0==TD^_YI MBW"TCNA^6+9GTCAT1_X'G=R$+
MA5J,E2[[@=P:R4E6I#^<(A\YD^Z3'^T,HG%VIS>H]K2? "FI7(QXU8N%\V.Y
MMTQ6WCCB<IHO\UGAK^IBPU7.E$/&9.X<AN.XOQ?MVCSN))/"AY#P&M2+T[8:
M5./+(G2AQ<%G/G!R[R/U/%K6G$S6*_2R,6: Z\0MM$2!X>^)2EC6E-JN*B'F
M4#U85O56?5@-H/FR5G2,%HNR+KVCNT !K24@,%/9$%9#Y0'+1ZN6X:*AD\2I
M5-. AE4O>*B+BAW 93D?O#+D,GUV04HL^H5+ WUQNR0F9"$_AE4QGID^B_;&
M4\"U8<.D] +;N[ZE!+@T>^-3( ZZ[-=XNSA($CZ..16)NW-%'K-Q B-\Y=AV
MR4/!9C=<9:TPP1H1-3A".?76S6U_;7PCR:GFIOV-Q"IP03'6SL4\81-\G(L!
M@-N.MNFJ!679X#/PMK4F?WIUF;G5KX;.V- UK\HEW]T-Q20&&Z[E2S=J$WR2
M?_+>T+DI[MJ9IVK2Z$$N6*K5N%_46)C7BW&@E[3P9&+T36,F.47L07ZWW":@
M<Y%A5WR5WSNNPEL]X6P?\$U^'R3 5Y^1 (($^.KWB03XS4GMK%3[\P4%J> Y
M8(7V+C;AW=)TL*5B<FP+F&WGQ/LD0.R>]/=MP:SDA0WF< )B2;PN.9L)'.LG
MZV9H&9!6?"@%X"1!-+HJ/%D46U"!UN=[011USEHZ)^Y]'Q>=NAK<YT(B.U%V
MX$WRXZ-/LLG+M.F=FV !1Z4I,LY[XI<W1:;RY/2)P&A#"M59%3PE*$5UP$6M
MH74\ZIG'[,I&2--DXZLBDZKFVHVG%B'Y7+=;UPGD'HY#+9FND#D[S=*NG]IV
MD1QL:!SW.5EX^'-I]^(%E5V,7"[&&RE/UA4O%, 8 ,$)%R$Q.#_OM!40DG;S
M:"02/3:<- A]P/?C;*6:YF7<&<:MW-/C(TL$%[C!@;1TY2ABZ$-4)F'O^E)/
M!*M"Z4T<2XF3S?5]\,P0%Y ;0("$(!L/"<A3P 5X'@$7LFJ-7+]QL(WCN6-Q
M!]M4>DW86>Z-PDV7R$LT;A[#'.XS'8X ?.)\;'0>,3S=#7*5(UR;RN&CS0P!
M&OBP=?&1@,DQ$]B8!-P5_T\W7/!<D>.5&0]WTY6;HA.) @7!VF."LE#+N_$2
MP/LDS*EW8;U)R(^CL"[PVY'SBO-K5"/79/_]G_^39X\>/OHRCYH=6-7-+)?4
M[%L<:4G']UN0<WGUH,U/.>[F0_!6UPT*H1]7)]+R3- U5KT9=8H&Z/CH7(!(
M"&(!FTT, %ABC'%HEHSAZ3I%]\C&M"V;&$'XZS9X,OYL2RX2.[X3-$AM%RVL
M#Z/+F1L7 ,B,-BYW*+<2AFR$TMNLM,\FHJ/G*L(<+_^HX6E!F7*,TY1-ZOV!
MS!*Q19SRZ+8:RS:>J>WUQ0_*E5T2Q3Q>AI0!8<\8$4 ]>?0$NWYFYQR:I_MW
MSWYI1SPOL2J@F'D-ST&N</*T9&:FN\FX$=$GOU\/,1'9:P!2_C9=X2=;>?=A
MIS<OJ^4XP"F 2AK6MAFZK5@8K%VH-M&]%WM<D<F*.60D.QDT"!I^);)CZ&MB
M U5DA_M$&WR#;&X<LGMO[[Z+(X3-!^6/8O[4-^U 2CM<\I!0+):AQ'K3D1WI
M)[?93H+N]0*.G-@7A,]WNWM;] &R+R4W3@*R3Q4 EW/\B1(P$H#L7OOOOG!\
M1-_PNTN[+4UG]FRSJQ2I,5+K6JA5'=A%3**LF P71X.K#@$]:"+GD92 [VCO
M5%QZN[GR='7P]NIWT-A7E12=H"Y_@9MQ^>!,<5&3G[<2T;*%89282_0C/& C
M_$J-\&=L88DK'B6<%L&'HT2[$VB[F%0[O0<V?.48EJ(_:[%731U B1::W<\[
MV3P%>F9:G+(-U.+]AS8Q-1;U35'O-9&Q_8?"K%V;*,X0&*<@-@L&0:[;?J">
M/H1H9$-Q0^ULJH64PAFCZ.*C5'"1Y6>@ G&3,TMFB\FR=H<FN$"7-Q8?E<IU
MV>]EF[IH^C"=MX=3%UU\>5\_&E7TGN,C_:J\T3<SVO-.[45':A/,M&5+"2**
M-V "F8H4L9$>EPTJW77'UI7\M3=5UA@=BFNVE4<6HS(U!8EX+3V:+M5:#G0P
M!J[%N,,!V7T(UND"-#UX4:SI/>!<V7="BZ7\"6)RFKWQ8D+W7MSR$?%K'+="
MP76I-CI$JZJC%Z^V/4;%#$"=OI/S_Q!VG?*>U<9E8QCQ9B'LA.MS7RMUD>_
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MHT7,HLD":@#A\>DC<4L/^<(N"KVQ7[>$ +SB;IQO$-=#>ZNW]SG806O7V;-
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M1H#77$S.XA!FI1$MU6TW@_8,"GZED;2"F)V[JE]6/@*,=GI3$C\&)34D<1$
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M<],\/LNS1P\??4$_B/_ZQ#&W'A_-2-.Y4TOSZDIA'SA1JSJH7+ET,(<$GN6
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M239&U4E2<"N-D]M!?#$EQQAE\E(C$=HF.JKC1[E5C[E]DL^*<G.A@J>3'["
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M5:/PO^/7O$F6U*&&5X$.2*C E<A@5"1%!F::S*WJ W+0F,F%TO%T@9.X>_4
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M=5_EP3#.@"PD,13RC2H?S/JLRL?OJ<ID%FB_-OP5V!MHU>"T<>/W+[>9!DE
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M/Q1 !),1=IK=?),^)$!XY][GV;EK09K_7Q:[6[@9_IS]_8.XG*3CR!WF]]V
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M:97RKH1M4P$M>5)UQXM!-VYO69.<?_CIXG#XO_M9OLJZ?_#PQW S7!M.FI
M1L_JD)9#OWU4[RYB]]C).BLQ>2 +^$61QVZ>N'E^F9%L%?RW"AEM/B6WQV:@
M/^% KSC2+*2334#9"NM(XPEL&9,4H/ 1;?,4#W0_T>.&PD1X6$C,B&,5L[9P
M&O^J\9262W=&!/@$%Z]:>/!U):*AM]S>HGNJ;#/NU!!1$FE*"B.#6^X<T(MQ
M =N7&\@RBRDT&B<DY-G%$P<UU,MT4E#0-V?T];  0M;.9A%\'8O@_5:!,PZF
MA42C I$&5!$ >RUC06R4JP9!)*^;%%T(5R^),V - ,]PE"FZC:Z*,<QT^)2"
M)N!Y9E7KFO$$MZNLF\V$_"HFY/5J\S%K3@?F25]Y@I+H'DIVT=:]<)KNQ!W:
MY.GK#UD$=SR"^9LSE+E8FG=Q=]BYZ$0UWR?V=C"'8:4ITKXEC>.CK,+H+Q($
MFU6X645?X2KZR$6$<[4K_KYF6$HC\ Y7;.;"5S$75CSA00=QFOHL$0D,8CU2
M*%<=1_\[=S]&1;^D<+WC7@K.>%2'3+)KE!SRZ6;_&>8ZTZXH[&!Y52 HQ+OK
M'(66W.TV$^SKF&#O84-&PZL8M4 @#9K,*=\54W4=ZU!O1OTK&?75-Q: Y&@"
M'3 3L.11$]E(TD(6F01-4=T#0Y+.+J)#B,2X5'TJAGP5)/JSLAL>4"!M*Z[Y
M:&7?("K*S:S["F9=]L=J<ZZ*QRWH!@Q)APK)24O0>WL+3""JEYZ.G4%N?W(&
MY73[>Q=/'NP;O%T0(D__<+8XQH[S.EAN]]YFV5>1;0HD5&HZ4B0;XW-/2_/6
ME/&@6+MR*22&JV8!OH5W$VOQSJ?N6R](+1J;4Q5PM,BYD3XU%:T5T,DQ0E4<
MQXA!C:52=20OT<GJ-*D& W&&A2"++GIB!*_3=D4WS$WRB\^AB7S<,%9I]678
MGD6XI6&1YXROP:2/IJCD\22N[/L!(9:A-@T!C32GUD)/T1*B5$X'>"PXG8QM
M6SAZX+-?\YI3_7$.($E7L?!.T;PJ_@-9 4E*U.;&K!YY.-P\G,'+N/GF)@E4
M]"/(BX@4\*2I8)OP^*' ;Q_)G*BQ'=#4@#G$S\IR2-X#'@.FAKZ(WMQ,A6\,
M>/'<>09NC4'@N9%TWMZ"#)_'Z.(DSET+<'TI3E,FO%N%F<]RVDV]!5OV2SUK
MG7$6%N\-ST5M3(#V^N=L;R$9EJ03XSPOYKF7)>?TXGND9[M&#4^Y'2 K"; Y
M8#1D&DP0O76K#0\[X*>IKVZ<\-).F>?^=99#;YDYI -O!H?LDM4*(EC!B8O&
MW(H/^L9F]DJ0HOT-I$@@1?L;2-&?=BXOP^$:C5!B],5]30TW5/6LBZ"W68$8
MIIRX0[S,,'B0S(<!^U8=<4G2R--Q2GKCKAEW*7(OKJ!1EJP0<UN3Y0:X!P!Z
MF^\3]$Z[GBPX"WA1$]4,7UW4=)BY1T.J9<*^3(L;%I#6TP&AQ$2GK%UO>Y[Q
MQ4UK;>&#&+7EGI&XE0C>#F;M$HDFSE@;DGNNY2YH4/K:"C&.M[>TXFC(]4+<
MA1\Q?M_8T5*?0"Q>[8:"5V,WRMI0O<&45Z7PB]2M(Y'NS-@"OOOW.Z9X@M#%
MK)#-I0O@=HDB<'D-MJ^(%[MKI,#.ZQF[9U[X2R#+)7@[,?=EMEF?D-=LX U>
M(/(ZH59@U[!^J>TR7> ,M6:H(&:O6\KO-J#W0>NF/0$F/I$&YC*DH.!N4B24
M5L@$DD*@.8M+;T&D&]7;AM"Y&4;82[59EBO1UZ"02"VKX7*Y15N$B$*2\8UF
M2,]GG*Y5 CYI,Z$&Y5QR\S0?9E,.3KGGC9P=3Y4E<#O \]<I)@-A92!%A%8G
MFN*5OKIA_7$J)\(B1Z@N< L-0JERE1OC'!C@8.7,>+=T#VX<,\Z_Q4I0[ BS
M8\CNW3:\ND=@.1"V$&K;9FD+O,A(T]<0'>%. L/DCUP^..J'.R-@[>D[!,UK
M>.QU,8.^YNJY&)I<29<&QX8^P3DVWM4NQ<FA3<$X:5"!@V^72.PZ9][#ZZR<
MS1?;+INMP%? N.E\D1'PO,@E[%^4-.WB"F9%&PBAM<JMYD!K#$OOBKD!O"<O
MIJ"@5\6/?4I2D>,A;.\S%;]\(3J5O_SE+U%#[@<%?MPW7XH]Y@['^.'&,1;'
M^.&WZ1A_)B:E&J,HZ/V MG:#@NB?FSV>S;V+U$OW0![@IL"Z:( .#X$T/RT!
MH.::P%!0KI2] N,@?@?_6UP2"P(5<*AG">=NGJK%0(H#:R8Z_V<1UU QG4VW
M?EK= 6=[X!:^Z==/V0X2]/EK]%J95#(LC5X33J<OH+'[;<V?/T<[_FR'_+-;
M+,D%7\V4_7*\1>,%GJ:BB0@ +UQK7N]$!]S[&=[N6+T7UHH]AF$Q'L?3RIG.
M\E> FUK=,_@.#>4E*"LROK\3>WIP&!V<0L-._O;=HP !]N FA4 0_&*<-$D7
M$83$MVA5)?_0-MB;?;HGN,GW-+RE?^;#^F@L\=_NI7$U\-JC[]N?4[OLR?<D
MQE=_K]K-'KK+?HMG5W%YFY/KM/3Z'_;"IW]8;[=V$YZJM=;^>G"5I:.H3ZF\
M:V0_<N=1N4H/&_";7>.Z<A?O=>:2E?+FCWZ)3@G.]30ZAL#@-QXC>+1ZC.!N
MAWWA>,G_N]WU]/!WQ#R^'+PZ_O7_ 5!+ P04    "  'J ==7EFQ(R1%  #\
M8 $ %    &5A,#,P,3 P-C Q97@T+3$N:'1M[7WKD]O&E>]W5O%_P'JSJ>$M
M:#QZV(XDQU6CT2A6K5Y7,X[B2J6V0 (D88$  X SXO[U]SS[!8!#R9+L2RL?
M8@T)HKM/=Y_W^9WO?[Q\_NR'\>C['\]/'\-_(_S?]Y=/+Y^=__#]U_Q?^/9K
M^?K[1R\?_QQ=7/[\[/RO7\VKLGT0W3Y9M]%EOLJ:Z$5V';VN5DD9\P=Q=)'5
M^?PK^"'\]-7[_NYAM$KJ15X^B/#1DX=1F[UK;R5%OH"/ZGRQ;+_ZX?M'/YR_
M6^;3O(WN'=_^_NM',.M7GV*\65:V6?W5#W\NI\WZX2<>!%;UZO7YK2<_O7A\
M_C@Z>_G\^<L7,-#+L_^.7OWT^NS'TXOSZ,WIZ]>G+RX_PY)A-KKJSS%6?K'.
M9O"[,GI:SHX_ZI@???N^^N%-4M=)V487RZ3.F@?1__#__OR?]Q\^+?,V3XKH
M_%U6S_(FBQXG;:9/Q-&=DSO??B)J_K)IVGR^_<2GU8QR^>/3BVC? SL>';7+
M+/ISD?Y[4ST4\OVYIK\F< YJ>&<.,VJ721M'\ZJ.KI)BDT5U-LORJRR-E<3\
MOP@>R-LF2IH&)M5$[LM_K(HTJ\V[\R:"4Y:W!;YDLZ[*\0@?AG.W@M^7:=1L
MIK]DLS9JJPB_*/)5WB9M7L%KJS+*=!OQ4?Q^5I5ISE\OLSK+RV0.[XJ:K,5I
MM\LX2EIX>!NU0%%\ TR5'\%?IW 8[+/C43*MKC)O^KWGQZP&9[&!Y13P-EB9
MGD-<I#R?1GD9S3=%X;WU$I8+4\5Y^R^<;MJHK%HB2IW11&,D!5"EF=7Y-*/-
MP&'7FWJV3&!"\[I:1?Y]A45'C[,BN8;K !2JUU7-8[ES.*M6:R",#HV[@2/)
MCC9TE>"<)(V[)4F*!P[&:8G<FS*E"7;.DEQ%LZYJ3@^9,1O\N,&_5S"MB[::
MO3V.+N$)LZQUG<\R_%U59N,130?_<G\1T? ^Z>%!H#70*?OW!K9-3I'9O5?X
M5B!/$Z79/"]Y>RY@<4B=.T?3R?&GOJ>?@Y&[@^GB;A_#D8 E\V4AE@YG!3:4
MKP]0RKV)2IVL:+)KW&FDDTMHWO1Y5135=5XNY&?+!*X/?K'*DA(^;N!G:3Z#
M$YZ:%Y@)/3@T4LL5.)W/\R*WMYI(C01IB!&]RNJ&V1[RUC0'GMH66V*AI?FK
M7=;59K'$PX_?K"K: 21REN9)G>/D@/6U=54T]--&_P3&&DVW\AE?D!G?&7D@
MNL[;)3 (GD<,3 ]O^&RI/!A&V@C?0CX#OVK:>I.E\K+7FR*+[IU\8RY?ACNZ
MJ>$4 0E/9^W!W2#9UD=YRNRCLZVQ,.7M>(0"A:\&\Z\T:XG5\Z;0E<GKIE5^
M:._/K$B ZBQQHV2]+G)49(X2D)B&=5K&E^.#P.R+O,&K!:/#C.A?L&G199VD
M\,[QZ'E2O\WDJDYA^H:G=EZ("Z#;CU(2=O[?FZQAB2%?E!GR\Q9> 2H OIUD
MYP0'Q*]ER(A'Q$^OESF>J24P[_VF#L>PSD!2M4RK1T55K:99O8B.IDD3+ V$
MYI8%W_T'=T^BY'AU'!WA/O]<U6^CL[QE>3]!_G_OP<F=: U/@##K>00$'[!]
MI/++R[/_^P@GA/_X!TX4)+$SIDO-JZK8 *6N,[2 </)769TLLALH3-<,Z093
MN9FNP7R /G0N9LFT@#-V-!L\&CCM?AK3-LMR=(3QR X!]QW>28MHS)GP7H_L
M@=YM]@J^0L']*B_?1B_7\(V< 5QA$C6@OQ5)#7-8@$3X7U9#\)M%5LZV2)%9
MEO%IA;U")7*^*6>B[\UE%)PN3VK"Y%]50#*D&$A\>[#7J/BIHM"9>5.9.<<X
M@Z-T0CP.U(4*M:UH!L>LB5D*SI.\1OZ "V'5%UZ91/UJ"&D3[CU/2N3E&1 C
MQ1G"MM4):!^HEA; WYFY+JHJQ7& &0MK8%69UIV,1ZODEZK&8YJ7S/HSRS=$
M",M5JC9MT\+>(9EP"T%Q!,X.QP1F N1=MWAB5!42%4SD=Y:QUIV]@\DB_X$!
M^.:J(C4>K9/<<"_Y]<'R^$T#>]@TR%_ZI7>: )?G\P*L&DY TFYJ^! &!(&8
MD.#EK^D/Y8,H@E$%!95TFI1O42^B6T-\"&AN&!.>KV33+F'K_Y>O;@V:+*@%
MM 6@TN,^UMDJR4&%F!45<,:'</RKJSS%<[VLKK,K5,GQ\H), 1J@^@77*>[.
M@;<8N<44)54&N@6^?;KW#"*> (B]#9TOH2(<QBV:7<MJI<(R-M\MLP+.\JV\
MO+4NDEGG^[(J;\$&H(T(\\Q6ZZ+:9OI4Q&)6"&Q9"]^:>CS".P*L0-@'LR^<
MXX9O+?YVO=PV0!*@ =P@V)FBFHEYF;1L$Y(.1FR*?[$ F[ NT>:!7PEE8->
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MG>+$FYP-?KPR$WMUZ6)M56%Z"XL\N*WUAOF/6[>B)WE6I ^B5T"CA_"N?V^
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MKFDPDY#Q,06&OD&<KKQ! L^*+*$:$K?_J2BV9/8HK)H!2YOT3]KI['.#P_^
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M]C@Z1976;(ZH73?M"26F"G"R+;>V*,C?W@;FE_H59YK;X0+[!."_?(=ZEF(
M5QV#IJ)NPX)DDV,^SXIAXBE.($Y)&Z/6"A7N+T_\%1W)[;:+%X+B.*0?I?;4
MU$4MF)'V=U)%3'NK!E5)2B2*I1#B84-V@!D=^UL0T*(E_GC42WVQ2JVUP!52
M*\2I,!VUD.IK(0K84QGZC*CQ6TV%W;4FH "U09X7#!\;^NFL;2)[8S]H>JR5
M<)OHB+%5;ELH+9T\RT^1C?X[Z>ZP;[O9;[X$T26(_LT?,XC^.SFO!HCG.#K+
M:JK./35)-\TA-B9AB?LXIQS E,V[BW61MS8.$SV=>Q6Z?D<1X/#(0P.KV]$,
M&.QQC; /"8?2& \S*U._KSVR;FHSB7 EJK,BIW;^;@CFR*HCJ/#Z*DGM.$LE
M>; R_W*RA=W>PY)2F9=#BLX1R3'I]G95Y:E)GTBKS;2-G0B3VWUTAVK9;0"T
M4^N9")"B-##'CGT.B<>CH9%*]@9C]D;=T>=B0>F;5:LIB+#&R8:G;'I%GT>+
M)9.M:_!L3/H- ZH2[@S>K+"6JV]T O*XFC ]&D:=GQ6(8$^E:N+0L4M3:]H:
M[AZ-9]+-4AK"AU84F7Z>_Z<GW\VFOWB9<8F7$VA3 6%-B-A<.? >^UG01QQ%
M(9L.E<Y-O35DT8*#(>U:ZE<XI9"T=\\71G9=QH#1X<S<C@H?I-/;0:T[K//*
M_4PG.K22L@/J%RN.,I:" C*^KUHT@U@BH8G +^9($BCDK ZFI.:[D,R4XJ2!
M77&N.RHOHK$9ZA$2B]7RNY3AV!5!LZ1:8LY;$3A2G6R"QLL8E9)PZ?'@\DB/
M(YH&R/O.RGZO#6*-#XH37)FGL(>*>8%8B)3F<,N_D@>2D6"0YK$5-6.R2X5D
M]!+HA3DW;B9"3Y6</4C]18]T?,@7RU?:D9DNVU]0U7"L3+"BWH %M\$>"O;Q
MSO!LW53CAKVBVFDN]IQ*M6E4A[9.BP4.%8(Z)A:CG4ZO'DV)7=+N#_,+'\W<
MP$<P*4V9%S-?QV(GVSG(F):FV[%-UF9;U,&849,L&$>"098_!-]W*]=FMMS&
M]/KVZV"P\H9<#7MY0O@EG)]!TZ?X6]8.)YR#3B&!7IQSG>JQ<HU+EWL*N*[C
M#.P+%/M^BW[3>=(G38PWL-(:J$0/!$*)@6I6&I:V8/>C=>74D<+"]>X.'E>Z
M Z5L7_#BV([N^B+[S^30!IA$2<<1ZT^8DTQOG&YT-)2NV9/?TQ,YL]4O"M[#
M3%=Z*"_'(W] 27+AAD[*G>40LEM.2X!N#%"%M\SMR> 7)]BID1^PAPX.2A0M
M]X@J9WNBZTK&X>!*HHOKI[B.A*B .-3$9NONGI+1'^B>(HFGV99.I&Z\T,'!
M<D+^2V>1]Q7!@EJS9YPDJM"[''[_M;MR*$BHII?#*Q ;KU%L/';M,FLM/B;0
M<]%B&'<H0*?R[<-.)7DC+;1 \M1T6U>*/=NQ&P-;D>U!D%<97F,C([G5/+-Y
MYPGR9][(66+/%.(N)M;6\ S8&[)XN XNG#$CO35JO(81\]C*:_R6^S4Y4TH,
M4> E:XRCS>=QQXZ*'9A!,#=P&Q:,[L29')PZ[GSN3$42C)V*]8E3S^T> BON
M^U&G?(A1-Y*%C,N)SDM.RQ""X@ G,^GY[IR4:6,>] #G=FMOG==QTS=R,G\<
MS2#Z,,6 3^]'U@SZ6=4NQ8!LV%V:08?T:.!_?+$?.!EVRGV[FU(0UST>OT[8
M8]GQ;FGOC_;)1+T:T[ME_> -"06]3&U(W@_[MAC3/Y3W.X:;V."=S>'I_NAF
M4<]SM05%'R3ZHR^2_\.J(+_]$L"1 ,ZW7P(XOQU*_Y--F28K+OFZM J+&\J(
M3:O0_<(7L>E593S)7.97;#F,K7]1/AMF,:'&RDE9G(_G:$Z-..,:3J)=9>27
MYR1!.N#&2^@JQ!0=I[%($W!+-9S^2GXIV39"QU8.PKS>3H:G+--AU12MXC@J
M,E*\BGR&A96Q=)05*%#)'8LYD6FKYK]1QDUWB&K.%9NH%TR1EBTGCDL9)[ES
M64\/<^$M%1/0@VM)B.HCIL8OG$UQUQ>[G6AITJVBXTE3\DS3'/F3(\UQU;I'
M)W/.)SM!>*HFYX,XL!+C:"X==46 ]UDZH[//3LR9$HR6UR:P,^\U#0@5H')<
M>BA+#;XW=_^U@29G3@M@-ZU6CWYS8C)^7.>_+]9AE*$?7564C;?&SM#ZV8Q_
MK &X(!1#49\/N%*(F['[3O58/J <UXNDE*;J4KK'YIOYK _L6GI+P@PW15-I
M?,9LD%\29E77(-)GO>_%-K(%(G25G>U.]]QA#IH%U!N/?@U'0M:S6:TXV]H:
MHKQ:<X,2Q0.VUWVZ:3!JV/@Q@QM+68(-B3O;P8;L+3)D+8?L-5,GFC/N7DYJ
MR<H9TO"TEK11FT4%VPT>EWQJ<1$T>UV/H?"9?T_&HU]Q4:(CLH:-K3T@W7PO
MN[C/V?[0T(;3QJG/]O8M[#ZL18I,.2#S/G#>((*5-7N#AA<^T)+;SQ SY.O,
M10(86':\"TGL9N\Z)7I[V6W5;H28R9Z5@#(/F^N%G(1.5EC'7=7&6K&YONC#
MTNX=S::^XB1*YV>V9G.X>[ 3DCDMX"QB7!5FZ3QC^L[PWM)&(3!1QW8;H#Y'
MQ=TTMCU(8X'8=E61>$F\YG#LG,P^NQV]UV;[!0Q<4*,FO8_CTPGP[DHK2-;(
MR>L\B'-K)JI9Z,"NC4=>IP:+U#7PO+V$/N0&"H6FM\.Q>@B&+QV;ZQ81WF0Y
MBOW>LWR8IYC,@_,L23!@4PZ:KF2N2EF&@16FVB)@,%=H:XHG J4?JF\HFU!:
MP]I*JU8.#$@PN+N4-$P$E<J 945K," .N^0S.>NFF85WIX4-$K,_8#/5X8WC
MLC.'03JV.G0C@<A=9?)P(8NBNB9QMF/3^U S&"Q8KH0P.O(Z;3M+IL:7YJIZ
MK9>#8D?+\U#+<9C8A1GCG,8PW LO#ASQ5>;6A3@VAH-_&&8$]37SW@MT-D@2
M2?V.J%H%8Q0F*L><$VP*A;6FW*@<=5DY[FAY"2AK50?=8)C9(]=P&M^$,FY3
M.E<GA4N"75KW8IS4\MB'&.\'YAS$%S4&"SOB'&(F>E.,7A-NHX$>9*B9Q! O
MI[1V4C=]\U&C$;TDC32#QT+>Y(2SX(D7RN'C/':L:R5EKC=AR\LG,_*PLX8C
MJ;M9)\2"^!),W%1#Y1LW!@BXML[(8[R_PYK;G@D$.Z7<?J<DYF.B,)SF;0S
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MZO^&T82%)U I,]NP&>( HI-G@TI/DW/)M3QW)JJK[J2[%Y'40.9UG5U5Z,[
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MV8%L[,)F794D*#BZ?RXWPV[QBXH$6B-=UK.$;K2I1RX2$M=.^;+94,NN'/V
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MX3JB_)8 VG+T4/;US@08(A-)4 "Q2%YJ_:E#RA%L F(#&8J,1]/JW>3!9R;
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M5#(1"64SU9C0^.&@HU0L2Q=:[KK9,6ALB!DK#4I%J'N"$(]*<NZD>'7:H$1
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M%:B-JR!;S2(BUT(SUQ*AW;MME5@J(X+IF##3E"G,/7-/]&2%1!O5-1?CSR1
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MBV_<+_<65KOE?U!+ 0(4 Q0    (  >H!UVS_]K#,!<  #:J   :
M      "  0    !E83 S,#$P,#8M.&M?:7-P96-I;65N+FAT;5!+ 0(4 Q0
M   (  >H!UWV^QUB4$\  )]U 0 5              "  6@7  !E83 S,#$P
M,#8P,65X,3 M,2YH=&U02P$"% ,4    "  'J ==D=DDYE6D  !47 , %0
M            @ 'K9@  96$P,S Q,# V,#%E>#$P+3(N:'1M4$L! A0#%
M  @ !Z@'75Y9L2,D10  _& ! !0              ( !<PL! &5A,#,P,3 P
M-C Q97@T+3$N:'1M4$L! A0#%     @ !Z@'77="R9NZ"0  3!X  !4
M         ( !R5 ! &5A,#,P,3 P-C Q97@Y.2TQ+FAT;5!+ 0(4 Q0    (
M  >H!UV([RG,@PD  &8?   5              "  ;9: 0!E83 S,#$P,#8P
M,65X.3DM,BYH=&U02P$"% ,4    "  'J ==WU!D&R@#  #E"P  $0
M        @ %L9 $ :7-P8RTR,#(V,#@P-2YX<V102P$"% ,4    "  'J ==
MU_ -]/T*  !_A@  %0              @ '#9P$ :7-P8RTR,#(V,#@P-5]L
M86(N>&UL4$L! A0#%     @ !Z@'76#U<_%9!P  UE<  !4
M ( !\W(! &ES<&,M,C R-C X,#5?<')E+GAM;%!+!08     "0 ) %L"  !_
%>@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>ea0301006-8k_ispecimen_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ispc-20260805.xsd" xlink:type="simple"/>
    <context id="AsOf2026-08-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001558569</identifier>
        </entity>
        <period>
            <startDate>2026-08-05</startDate>
            <endDate>2026-08-05</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="AsOf2026-08-05" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2026-08-05" id="Fact000004">0001558569</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2026-08-05" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2026-08-05" id="Fact000010">2026-08-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2026-08-05" id="Fact000011">iSpecimen Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2026-08-05" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2026-08-05" id="Fact000013">001-40501</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2026-08-05" id="Fact000014">27-0480143</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2026-08-05" id="Fact000015">8 Cabot     Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2026-08-05" id="Fact000016">Suite 1800</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2026-08-05" id="Fact000017">Woburn</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2026-08-05" id="Fact000018">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2026-08-05" id="Fact000019">01801</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2026-08-05" id="Fact000020">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2026-08-05" id="Fact000021">301-6700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2026-08-05" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2026-08-05" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2026-08-05" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2026-08-05" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2026-08-05" id="Fact000026">Common     Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2026-08-05" id="Fact000027">ISPC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2026-08-05" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2026-08-05" id="Fact000029">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2026-08-05" id="Fact000030">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
